<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutrients</journal-id><journal-id journal-id-type="iso-abbrev">Nutrients</journal-id><journal-id journal-id-type="pmc-domain-id">1692</journal-id><journal-id journal-id-type="pmc-domain">nutrients</journal-id><journal-id journal-id-type="publisher-id">nutrients</journal-id><journal-title-group><journal-title>Nutrients</journal-title></journal-title-group><issn pub-type="epub">2072-6643</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12429899</article-id><article-id pub-id-type="pmcid-ver">PMC12429899.1</article-id><article-id pub-id-type="pmcaid">12429899</article-id><article-id pub-id-type="pmcaiid">12429899</article-id><article-id pub-id-type="doi">10.3390/nu17172804</article-id><article-id pub-id-type="publisher-id">nutrients-17-02804</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Personalized Nutrition Biomarkers and Dietary Strategies for Atherosclerosis Risk Management: A Systematic Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0004-1153-0143</contrib-id><name name-style="western"><surname>Fayyaz</surname><given-names initials="K">Khadijah</given-names></name><xref rid="af1-nutrients-17-02804" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4765-1276</contrib-id><name name-style="western"><surname>Din</surname><given-names initials="MSU">Muhammad Saeed ud</given-names></name><xref rid="af1-nutrients-17-02804" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bashir</surname><given-names initials="H">Husnain</given-names></name><xref rid="af2-nutrients-17-02804" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6530-6068</contrib-id><name name-style="western"><surname>Ahmad</surname><given-names initials="F">Firdos</given-names></name><xref rid="af3-nutrients-17-02804" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2153-7267</contrib-id><name name-style="western"><surname>Barrow</surname><given-names initials="CJ">Colin J.</given-names></name><xref rid="af4-nutrients-17-02804" ref-type="aff">4</xref><xref rid="c1-nutrients-17-02804" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8045-199X</contrib-id><name name-style="western"><surname>Khalid</surname><given-names initials="N">Nauman</given-names></name><xref rid="af1-nutrients-17-02804" ref-type="aff">1</xref><xref rid="af5-nutrients-17-02804" ref-type="aff">5</xref><xref rid="c1-nutrients-17-02804" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-nutrients-17-02804"><label>1</label>Department of Human Nutrition and Dietetics, School of Food and Agricultural Sciences, University of Management and Technology, Lahore 54000, Pakistan; <email>khadijah.fayyaz@umt.edu.pk</email> (K.F.); <email>saeed.uddin@umt.edu.pk</email> (M.S.u.D.)</aff><aff id="af2-nutrients-17-02804"><label>2</label>Department of Cardiology, Sheikh Zayed Medical Complex, Lahore 54560, Pakistan; <email>husnain.bashir@skzmdc.edu.pk</email></aff><aff id="af3-nutrients-17-02804"><label>3</label>Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates; <email>fahmad@sharjah.ac.ae</email></aff><aff id="af4-nutrients-17-02804"><label>4</label>Centre for Sustainable Bioproducts, Deakin University, Waurn Ponds, VIC 3217, Australia</aff><aff id="af5-nutrients-17-02804"><label>5</label>College of Health Sciences, Abu Dhabi University, Abu Dhabi 59911, United Arab Emirates</aff><author-notes><corresp id="c1-nutrients-17-02804"><label>*</label>Correspondence: <email>colin.barrow@deakin.edu.au</email> (C.J.B.); <email>nauman.khalid@umt.edu.pk</email> (N.K.)</corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>17</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">495755</issue-id><elocation-id>2804</elocation-id><history><date date-type="received"><day>01</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>22</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nutrients-17-02804.pdf"/><abstract><p><bold>Background/Objectives</bold>: Atherosclerosis is a major contributor to ischemic cardiovascular diseases (CVDs) such as myocardial infarction and stroke, which are leading causes of mortality and morbidity. The management of atherosclerosis through personalized nutrition has gained importance in recent years due to advancements in nutrigenomics, gut microbiome evaluation, and metabolomics. However, no systematic review has comprehensively evaluated the impact of personalized nutrition interventions on atherosclerotic plaque progression and clinical outcomes in humans. <bold>Methods</bold>: We adopted a systematic approach based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Key databases like PubMed, Cochrane, Google Scholar, and MEDLINE via EBSCOhost were searched using predefined terms related to personalized nutrition, atherosclerosis, nutrigenomics, and clinical outcomes. <bold>Results</bold>: Evidence evaluation using the framework of Boffetta et al. for cumulative evidence on the joint effects of genes and environments strongly suggested significant diet&#8211;gene interactions. Polymorphisms in the apolipoprotein A-II (<italic toggle="yes">APOA2</italic>) gene have been shown to influence body mass index and lipid levels. Furthermore, studies have demonstrated that omega-3 polyunsaturated fatty acids (PUFAs) can modulate microRNA expression, thereby impacting lipid metabolism. Epigenetic studies showed that dietary components can modify histone acetylation and non-coding RNA activity, which ultimately influence gene expression related to inflammation and lipid metabolism, improving clinical outcomes in atherosclerosis management. <bold>Conclusions</bold>: Integrating personalized nutrition into clinical practice promises to enhance atherosclerosis outcomes through targeted dietary interventions. Advancements in personalized nutrition offer a promising pathway toward more effective and personalized approaches to cardiovascular health.</p></abstract><kwd-group><kwd>personalized nutrition</kwd><kwd>atherosclerosis</kwd><kwd>nutrigenomics</kwd><kwd>microbiome</kwd><kwd>metabolome</kwd><kwd>biomarkers</kwd></kwd-group><funding-group><award-group><funding-source>Pakistan Science Foundation</funding-source><award-id>PSF/Res/P-UMT/Agr (502)</award-id></award-group><award-group><funding-source>University of Sharjah</funding-source><award-id>22010901112</award-id><award-id>24010901173</award-id></award-group><funding-statement>N.K. is supported by funding from the Pakistan Science Foundation (PSF/Res/P-UMT/Agr (502), and F.A. is supported by funding from the University of Sharjah (22010901112, 24010901173).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-nutrients-17-02804"><title>1. Introduction</title><p>Cardiovascular diseases (CVDs) pose a significant threat to public health worldwide and are the leading cause of mortality. Atherosclerosis leads to the development of various CVDs, such as coronary heart disease, stroke, and myocardial infarction. Every year, approximately 17.9 million individuals die due to CVDs, accounting for 32% of all fatalities [<xref rid="B1-nutrients-17-02804" ref-type="bibr">1</xref>]. Of these, up to 80% of deaths occur in low- and middle-income countries [<xref rid="B2-nutrients-17-02804" ref-type="bibr">2</xref>].</p><p>Atherosclerosis is a chronic inflammatory condition involving impaired lipid metabolism, arterial stiffness, foam cell formation, and blood vessel obstruction [<xref rid="B3-nutrients-17-02804" ref-type="bibr">3</xref>]. The disease is no longer restricted to Western countries but is now a significant contributor to mortality worldwide. Recently, the incidence of atherosclerosis has drastically increased in young individuals, particularly females, belonging to diverse ethnicities [<xref rid="B4-nutrients-17-02804" ref-type="bibr">4</xref>]. In addition, the risk factors that were previously known to increase the chances of atherosclerosis have also changed over time. For example, recent studies have questioned the cardio-protective effects of high-density lipoproteins (HDL). There is also new evidence that triglyceride-rich lipoproteins and low-density lipoproteins are causal hallmarks for the development of atherosclerosis [<xref rid="B5-nutrients-17-02804" ref-type="bibr">5</xref>].</p><p>The pathogenesis of atherosclerosis has been the subject of extensive research. In addition to traditional lifestyle factors like diet, exercise, smoking, alcohol consumption, climate, and geography, non-traditional drivers of atherosclerosis, such as environmental exposure, genetic characteristics, and individual gut microbiomes, are also now recognised as key contributors to disease risk [<xref rid="B6-nutrients-17-02804" ref-type="bibr">6</xref>].</p><p>The development of atherosclerosis is significantly influenced by genetics. The factors contributing to this include genetic variations such as gene mutations and polymorphisms associated with metabolic disorders, as well as epigenetics. This has been demonstrated in studies involving twins and other populations [<xref rid="B7-nutrients-17-02804" ref-type="bibr">7</xref>]. In particular, for monogenic familial hypercholesterolemia (FH) cases, atherosclerosis can be inherited following a Mendelian inheritance pattern. This is because the mutations in the low-density lipoprotein receptor (LDLR) in FH can lead to an increased level of cholesterol in the plasma. This, in turn, increases the susceptibility to developing atherosclerosis in FH patients [<xref rid="B8-nutrients-17-02804" ref-type="bibr">8</xref>]. Researchers have discovered that the gut microbiome also plays a role in the development of atherosclerosis. The microorganisms in the gut can influence the physiological system by regulating the immune and endocrine systems, among others. Metabolites derived from these bacteria, including short-chain fatty acids (SCFAs), choline, and trimethylamine (TMA), influence the metabolism of bile acids, cholesterol, and trimethylamine N-oxide (TMAO), thereby impacting inflammatory pathways within the individual [<xref rid="B9-nutrients-17-02804" ref-type="bibr">9</xref>]. Thus, understanding the causal factors leading to atherosclerosis can significantly improve its prevention and treatment. This was emphasized in a study by the World Health Organization (WHO), which stated that 75% of CVDs in their early stages can be prevented by managing the associated risk factors, thereby reducing the health burden on individuals and the healthcare system [<xref rid="B10-nutrients-17-02804" ref-type="bibr">10</xref>].</p><p>The most important factor in reducing the risk of atherosclerosis is diet [<xref rid="B11-nutrients-17-02804" ref-type="bibr">11</xref>]. Various international guidelines, in particular, the National Institute for Health and Care Excellence (NICE) guidelines, the European Society of Cardiology (ESC) guidelines, and guidelines from the American Heart Association (AHA) and the American College of Cardiologists (ACC) have provided the dietary recommendations to manage CVDs. The dietary recommendations provided by these organizations overlap, to a large extent. However, a few disparities exist owing to a lack of consensus and limited evidence [<xref rid="B12-nutrients-17-02804" ref-type="bibr">12</xref>]. These guidelines promote low-fat diets and Mediterranean eating patterns. In particular, dietary recommendations emphasize the reduction of trans and saturated fats, sodium, and processed foods, while encouraging the consumption of fruits, vegetables, whole grains, and lean proteins. The AHA recommends regular aerobic exercise, while the ESC provides moderate and vigorous exercise guidelines [<xref rid="B12-nutrients-17-02804" ref-type="bibr">12</xref>].</p><p>Personalized nutrition has emerged as a promising nutritional intervention approach for combating a range of diseases, including atherosclerosis. While there is currently no universally agreed-upon definition, in this review, we adopt the definition proposed by the American Nutrition Association, which describes personalized nutrition as &#8220;a field that leverages human individuality to drive nutrition strategies that prevent, manage, and treat disease and optimise health&#8221; [<xref rid="B13-nutrients-17-02804" ref-type="bibr">13</xref>]. This definition considers multiple factors, including an individual&#8217;s genetics, gut microbiome, and other unique characteristics [<xref rid="B14-nutrients-17-02804" ref-type="bibr">14</xref>]. Research has evidenced that nutrient metabolism is influenced by genetics, thereby increasing or decreasing an individual&#8217;s susceptibility to disease. Additionally, telomere length, circadian rhythm, and chrono-nutrition contribute substantially to the development of metabolic diseases [<xref rid="B15-nutrients-17-02804" ref-type="bibr">15</xref>]. Thus, effective implementation of personalized nutrition is contingent upon several factors, including genetic analysis, an in-depth evaluation of the gut microbiome, and individual dietary behaviours.</p><p>There have been recent important advances in understanding the pathogenesis, underlying risk factors, and dietary prevention strategies for atherosclerosis. However, despite these advances, the level of agreement on existing guidelines and strategies to effectively tailor and implement personalized nutrition remains elusive. This review aims to systematically search, identify, and provide a narrative synthesis of the studies that evaluate the effectiveness of personalized nutrition interventions, guided by genetic, microbiome, and metabolome profiling, compared to standard dietary guidelines, for preventing and managing atherosclerosis in adult populations. By synthesizing the current evidence, this review seeks to elucidate the potential of personalized dietary strategies in mitigating atherosclerosis risk, considering the complex interplay of individual genetic predispositions, gut microbiota composition, metabolomic markers, and dietary habits.</p></sec><sec sec-type="methods" id="sec2-nutrients-17-02804"><title>2. Methodology</title><sec id="sec2dot1-nutrients-17-02804"><title>2.1. Study Design</title><p>This study adopted a systematic approach to review the literature. This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology (<xref rid="app1-nutrients-17-02804" ref-type="app">Table S1</xref>). The PRISMA framework consists of a 27-item checklist and a four-phase flow diagram.</p></sec><sec id="sec2dot2-nutrients-17-02804"><title>2.2. Eligibility Criteria for Study Inclusion</title><p>Inclusion and exclusion criteria were defined as per the PICO framework (<xref rid="nutrients-17-02804-t001" ref-type="table">Table 1</xref>). This review was limited to studies of adults aged 18 years and older diagnosed with atherosclerosis or otherwise identified as being at high risk. The studies eligible for this review included primary studies dealing with either observational (case&#8211;control, prospective, retrospective, cross-sectional), experimental (randomized, non-randomized controlled trials), or qualitative study designs. In vitro studies involving gene&#8211;diet interactions were considered as supportive evidence. To ensure that the review was based on the latest findings, the timeline for study inclusion was set at ten years, which also captures advancements in biomarker technology, dietary assessment methods, and personalized nutrition approaches. Exclusion criteria included studies with the paediatric population (&lt;18 years); studies in which dietary effects could not be isolated due to concurrent drug therapy, and studies not focusing on genotype, biomarker, or omics outcomes. In this review, we adopt the definition of personalized nutrition proposed by the American Nutrition Association, as &#8220;a field that leverages human individuality to drive nutrition strategies that prevent, manage, and treat disease and optimise health&#8221; [<xref rid="B13-nutrients-17-02804" ref-type="bibr">13</xref>]. This definition reflects the broad, integrative nature of the field, encompassing genetic, phenotypic, microbiome, behavioural, and environmental factors, while grounding it in clinical relevance. Studies that did not comply with the inclusion criteria were not included in this review.</p></sec><sec id="sec2dot3-nutrients-17-02804"><title>2.3. Search Strategy and Identification of Eligible Studies</title><p>Databases including PubMed, Cochrane, Google Scholar, and MEDLINE via EBSCOhost were used to gather articles for this systematic review. The following keywords and their combinations (using Boolean operands) were used to collect the most relevant literature related to atherosclerosis and personalized nutrition:</p><p>((&#8220;Personalized Nutrition&#8221; [All Fields] OR &#8220;Precision Nutrition&#8221; [All Fields]) AND (&#8220;Atherosclerosis&#8221; [MeSH Terms] OR &#8220;Atherosclerosis&#8221; [All Fields] OR &#8220;Cardiovascular Disease&#8221; [All Fields]) AND (&#8220;Dietary Strategies&#8221; [All Fields] OR &#8220;Nutritional Intervention&#8221; [All Fields] OR &#8220;Evidence-Based Nutrition&#8221; [All Fields]) AND (&#8220;Lipids&#8221; [All Fields] OR &#8220;Inflammation&#8221; [All Fields] OR &#8220;Oxidative Stress&#8221; [All Fields]) AND (&#8220;Omics&#8221; [All Fields] OR &#8220;Genetic&#8221; [All Fields] OR &#8220;Epigenetic&#8221; [All Fields] OR &#8220;Microbiome&#8221; [All Fields] OR &#8220;Metabolites&#8221; [All Fields])). After retrieving studies that met the inclusion criteria, a detailed screening process followed. After the initial screening of studies, the reviewers independently checked the full texts to determine which studies were eligible.</p></sec><sec id="sec2dot4-nutrients-17-02804"><title>2.4. Data Extraction Process</title><p>The compilation of studies was performed according to established inclusion and exclusion criteria. Pertinent data from each study included study design, country, sample population, personalized nutritional interventions, and measurable outcomes. Measurable outcomes included clinical and biochemical markers such as lipid profiles (LDL-C, HDL-C, TG, TRLs), inflammatory markers (hs-CRP, homocysteine), and metabolic indicators (bile acids, acetoacetate, carnitines). Molecular outcomes included telomere length, miRNA and mRNA expression, and DNA methylation (<italic toggle="yes">LINE-1, Alu</italic>). Genotype-specific responses to diet were assessed through SNPs (e.g., <italic toggle="yes">APOE, CD36, CLOCK, PLA2, MGLL, CDKN2A/B</italic>) and genotype risk scores. Dietary intake and adherence to interventions were also included when linked to relevant health outcomes.</p><p>Following the PRISMA guidelines and the methodological recommendations of Zeng et al. [<xref rid="B16-nutrients-17-02804" ref-type="bibr">16</xref>], two independent reviewers screened the titles and abstracts of all identified studies. The same two reviewers independently reviewed full-text articles of potentially eligible studies to determine final inclusion. In cases where there were discrepancies or disagreements during any stage of study selection, a third reviewer was consulted. Consensus by discussion was used to resolve any disagreements among the reviewers.</p></sec><sec id="sec2dot5-nutrients-17-02804"><title>2.5. Data Synthesis</title><p>Data were synthesized in a tabular format, summarizing key intervention characteristics, outcomes, and biomarkers from the included studies (<xref rid="nutrients-17-02804-t002" ref-type="table">Table 2</xref>). For each study, relevant clinical and biochemical markers, molecular outcomes, and genotype-specific responses were recorded. In cases where sufficient data were available, a meta-analysis was performed to combine the results of multiple studies and assess overall trends. The meta-analysis used a random-effects model, and statistical heterogeneity was assessed. Forest plots were created to visually display pooled results and confidence intervals. For studies where meta-analysis was not feasible, results were synthesized narratively, comparing the direction and magnitude of observed effects across different interventions.</p></sec><sec id="sec2dot6-nutrients-17-02804"><title>2.6. Quality Appraisal and Risk of Bias Assessment of Studies</title><p>The Critical Appraisal Skills Programme (CASP) tool was used to evaluate the quality of the included studies. The CASP tool is a criterion-based assessment instrument for evaluating the methodological rigor and quality of the studies [<xref rid="B31-nutrients-17-02804" ref-type="bibr">31</xref>]. The reviewers used questions in the tool to analyse the appropriateness of the study protocols, as well as the presentation and significance of the results. Moreover, studies were assessed for risk of bias using the Cochrane Risk of Bias tool for randomized studies (RoB 2.0) and RoB in non-randomised studies (ROBINS-E and ROBINS-I) (<xref rid="app1-nutrients-17-02804" ref-type="app">Figures S1&#8211;S3</xref>). These tools contain a pre-set collection of bias domains that allow the researchers to focus on different aspects of research design in randomized and non-randomized studies [<xref rid="B32-nutrients-17-02804" ref-type="bibr">32</xref>]. Quality appraisal using these tools found that most randomized controlled trials were of moderate-to-high quality, with low risk of bias across essential domains, while observational and cross-sectional studies were generally of moderate quality because of residual confounding and limited causal inference. For example, the Mediterranean diet&#8211;telomere study [<xref rid="B22-nutrients-17-02804" ref-type="bibr">22</xref>] and CORDIOPREV [<xref rid="B18-nutrients-17-02804" ref-type="bibr">18</xref>] displayed high scores among large RCTs. Cross-sectional and cohort studies were rated as only moderate because of their correlational design limitations. Intervention studies regarding omega-3 and PUFA supplementation were consistently rated at moderate quality, indicating considerable associations with biomarkers (<xref rid="app1-nutrients-17-02804" ref-type="app">Figures S1&#8211;S3</xref>).</p><p>Moreover, each study was evaluated using the framework of Boffetta et al. [<xref rid="B33-nutrients-17-02804" ref-type="bibr">33</xref>] evaluating the cumulative evidence on the joint effects of genes and environments for evidence in nutrigenomics, which considers study design, reproducibility, biological plausibility, strength, and consistency of associations (<xref rid="app1-nutrients-17-02804" ref-type="app">Table S2</xref>). This approach allowed for the transparent classification of the evidence into strong, moderate, or weak categories.</p></sec></sec><sec sec-type="results" id="sec3-nutrients-17-02804"><title>3. Results</title><sec id="sec3dot1-nutrients-17-02804"><title>3.1. Study Selection</title><p>A total of 11,258 citations were found in the database search. After removal of 1629 duplicates, a total of 9629 records remained. Of these, 6611 were marked as ineligible based on the defined inclusion and exclusion criteria. The remaining 3018 records were screened by title and abstract, from which 2901 were excluded based on irrelevance to the review topic. A total of 117 full-text articles were assessed for eligibility. Of these, 103 were excluded due to lack of relevant dietary intervention comparisons, inappropriate populations (e.g., population &lt; 18 years), or insufficient outcome data. In total, 14 studies met the inclusion criteria and were included in this review. The PRISMA flow diagram (<xref rid="nutrients-17-02804-f001" ref-type="fig">Figure 1</xref>) illustrates how the studies for this systematic review were identified, screened, and selected.</p></sec><sec id="sec3dot2-nutrients-17-02804"><title>3.2. Characteristics of the Included Studies</title><p><xref rid="nutrients-17-02804-t002" ref-type="table">Table 2</xref> summarizes the characteristics of the 14 high-quality studies included in this systematic review. The studies were conducted across multiple countries, including Spain (two studies), Canada (multiple studies from Quebec), China, the United States, and Iran. The included studies employed a variety of research designs, such as randomized controlled trials, cross-sectional analyses, genotype&#8211;diet interaction trials, and mechanistic interventional studies. The populations studied were equally diverse, encompassing middle-aged adults at cardiovascular risk, older adults, and population-based cohorts. Most studies comprised mixed-sex participant groups, with sample sizes ranging from 99 to 12,065 individuals. Data collection techniques varied, including clinical laboratory testing, dietary interventions, genotype profiling, biomarker assessments (e.g., triglycerides, hs-CRP, lipoproteins), and self-reported dietary intake questionnaires. Several studies also incorporated postprandial testing protocols and omics-based modelling approaches (e.g., transcriptomics, methylation, miRNA expression), strongly emphasizing personalized risk stratification.</p></sec><sec id="sec3dot3-nutrients-17-02804"><title>3.3. Summary of Findings</title><p>A consistent theme across the studies was the inter-individual variability in TG response to omega-3 PUFA supplementation, which was modulated by genetic variants. Notably, research conducted in Quebec (<italic toggle="yes">n</italic> = 208) identified significant associations between polymorphisms in genes such as <italic toggle="yes">PLA2G2A, PLA2G2C, PLA2G4A, MGLL, IQCJ, NXPH1, PHF17</italic>, and <italic toggle="yes">MYB</italic> and changes in TG or LDL-C levels post supplementation [<xref rid="B27-nutrients-17-02804" ref-type="bibr">27</xref>]. Genotype risk scores explained that genetic variations, and <italic toggle="yes">IQCJ</italic>, <italic toggle="yes">NXPH1</italic>, <italic toggle="yes">PHF17</italic>, and <italic toggle="yes">MYB</italic> genes accounted for nearly 50% of the variation in TG response, emphasizing the potential for gene-guided personalized nutrition strategies [<xref rid="B27-nutrients-17-02804" ref-type="bibr">27</xref>].</p><p>Sub-group analysis (<xref rid="nutrients-17-02804-f002" ref-type="fig">Figure 2</xref>) examining the effect of omega-3 PUFA supplementation on TG levels demonstrated a statistically significant reduction in TG following supplementation (SMD = 0.52; 95% CI: 0.09 to 0.95; <italic toggle="yes">p</italic> = 0.02), although substantial heterogeneity was observed (I<sup>2</sup> = 81%). These findings suggest that while omega-3 supplementation effectively reduces TG levels, the degree of response is significantly influenced by individual genetic makeup [<xref rid="B19-nutrients-17-02804" ref-type="bibr">19</xref>,<xref rid="B28-nutrients-17-02804" ref-type="bibr">28</xref>].</p><p>The CORDIOPREV trial from Spain highlighted the effects of <italic toggle="yes">APOE</italic> [<xref rid="B18-nutrients-17-02804" ref-type="bibr">18</xref>] and <italic toggle="yes">CLOCK</italic> gene [<xref rid="B24-nutrients-17-02804" ref-type="bibr">24</xref>] variants on lipid and inflammatory outcomes in coronary heart disease (CHD) patients following Mediterranean and low-fat diets (&lt;30% of total calories). <italic toggle="yes">APOE rs439401</italic> T-allele carriers displayed a significantly greater reduction in postprandial TG and large TRLs compared to the results for CC genotype individuals (<italic toggle="yes">p</italic> &lt; 0.03), while <italic toggle="yes">CLOCK rs4580704</italic> C/C genotype subjects showed superior reductions in hs-CRP and improved HDL/<italic toggle="yes">ApoA1</italic> ratios [<xref rid="B24-nutrients-17-02804" ref-type="bibr">24</xref>].</p><p>Sub-group meta-analysis based on genotype demonstrated that the effectiveness of the Mediterranean diet compared to a low-fat diet varied significantly. The Mediterranean diet did not result in a statistically significant improvement in individuals with the CC genotype, with a mean difference of 2.00 [95% CI: &#8722;0.55 to 4.55] (<italic toggle="yes">p</italic> = 0.12). However, among those with the CT or TT genotypes, the Mediterranean diet led to a significantly greater reduction in the outcome measure, with a mean difference of &#8722;9.00 [95% CI: &#8722;10.70 to &#8722;7.30] (<italic toggle="yes">p</italic> &lt; 0.00001). When both subgroups were combined (<xref rid="nutrients-17-02804-f003" ref-type="fig">Figure 3</xref>), the overall effect was not statistically significant (mean difference = &#8722;3.54 [&#8722;14.32 to 7.24], <italic toggle="yes">p</italic> = 0.52), and substantial heterogeneity was observed (I<sup>2</sup> = 98%). However, the test results for subgroup differences were highly significant (Chi<sup>2</sup> = 49.43, df = 1, <italic toggle="yes">p</italic> &lt; 0.00001), suggesting a strong gene&#8211;diet interaction.</p><p>The high heterogeneity observed in our pooled analyses (<italic toggle="yes">I</italic><sup>2</sup> = 81&#8211;98%) highlights the complexity of diet&#8211;gene interactions. Differences in genetic background can partly explain this variability, along with dietary intervention type (e.g., fish oil capsules versus dietary PUFA intake), baseline lipid levels, and population characteristics such as ethnicity and health status.</p></sec><sec id="sec3dot4-nutrients-17-02804"><title>3.4. Personalized Biomarkers in Atherosclerosis</title><p>Beyond traditional biomarkers for atherosclerosis diagnosis, recent research has identified some personalized biomarkers based on genetics, microbiomes, and metabolomes [<xref rid="B34-nutrients-17-02804" ref-type="bibr">34</xref>]. A study in China found that compared to traditional models for subclinical atherosclerosis (SA) based on postprandial biomarkers, an omics-based model (ROC AUC = 91%) shows a higher potential to indicate SA and subsequent management of atherosclerosis [<xref rid="B17-nutrients-17-02804" ref-type="bibr">17</xref>]. These biomarkers (<xref rid="nutrients-17-02804-t003" ref-type="table">Table 3</xref>) provide more sophisticated evidence for the early diagnosis of atherosclerosis.</p><sec id="sec3dot4dot1-nutrients-17-02804"><title>3.4.1. Genetic Biomarkers</title><p>Genetic differences are significant (approximately 40%) in atherosclerosis [<xref rid="B6-nutrients-17-02804" ref-type="bibr">6</xref>]. The Human Genome Project showed that all persons share 99.9% commonality in their genetic sequences; the remaining sequences differ by polymorphic regions, including single-nucleotide polymorphisms (SNPs), accounting for most of these differences. These variations are particularly interesting in genome-wide association studies (GWAS), which help determine genotype&#8211;phenotype correlations. Genes responsible for the development of complex and prevalent forms of coronary artery disease (CAD) have been identified through GWAS. Furthermore, more than 200 loci for CAD have been identified through extensive cohort studies in Japan and Europe, including CARDIOGRAM and UK BIOBANK [<xref rid="B41-nutrients-17-02804" ref-type="bibr">41</xref>]. These identified loci constitute only a small portion of the disease&#8217;s heritable component, implying that many genes remain unidentified. While some variations have been found to have significant effect sizes, most loci show weak effects that cannot be useful in isolation for predicting the risk. Furthermore, each gene makes only a very small contribution to the overall susceptibility. However, the cumulative effect of these genes explains most of the genetically inherited factors [<xref rid="B6-nutrients-17-02804" ref-type="bibr">6</xref>].</p><sec><title>Lipoprotein (a)</title><p>High cholesterol concentration in the blood is caused by excessive low-density lipoprotein (LDL), the primary risk factor for atherosclerosis. These levels are influenced by numerous genetic factors, including 1500 different GWAS signals and significant environmental factors [<xref rid="B42-nutrients-17-02804" ref-type="bibr">42</xref>]. In terms of this, lipoprotein (a) has become an important factor in developing atherosclerosis. Recent data from genetic and epidemiological studies suggest that lipoprotein (a) may be an inherited risk factor predisposing individuals to atherosclerosis-related CVDs [<xref rid="B43-nutrients-17-02804" ref-type="bibr">43</xref>,<xref rid="B44-nutrients-17-02804" ref-type="bibr">44</xref>,<xref rid="B45-nutrients-17-02804" ref-type="bibr">45</xref>]. Guidelines from Europe and the US suggest that using an Lp(a) threshold of 50 mg/dL is a risk multiplicator necessary to improve understanding of each person&#8217;s forecasted ten-year risk for CVD due to atherosclerosis. This recommendation is based on the 2010 EAS statement [<xref rid="B43-nutrients-17-02804" ref-type="bibr">43</xref>]. Recent studies suggest that having an Lp(a) level of 100mg/dL (approximately 250 nmol/L) increases the risk of atherosclerosis twofold [<xref rid="B46-nutrients-17-02804" ref-type="bibr">46</xref>].</p><p>Although Lp(a) levels are primarily determined by genetics, researchers have indicated that dietary modifications can modestly and inconsistently affect their levels. A consistent observation is the opposite response of Lp(a) and LDL cholesterol (LDL-C) to diets low in dietary saturated fatty acids (SFA). Controlled feeding trials and meta-analyses show that lowering SFA reduces LDL-C but modestly increases Lp(a) concentrations [<xref rid="B47-nutrients-17-02804" ref-type="bibr">47</xref>].</p><p>A recent meta-analysis based on 27 randomized controlled trials with 49 dietary comparisons was conducted to quantify the association of SFA intake with Lp(a) levels. On average, a 5.5% increase in Lp(a) levels was observed in relation to low SFA diets compared to high SFA diets [<xref rid="B35-nutrients-17-02804" ref-type="bibr">35</xref>]. However, these studies used carbohydrate- or trans fatty acid (TFA)-based diets as an SFA replacement. Replacing SFAs with monounsaturated or polyunsaturated fatty acids did not yield consistent results. Similarly, a GET-READI trial conducted on the African-American population showed that consuming a DASH-style low-SFA diet resulted in a 24% increase and 10% decrease in Lp(a) and LDL-C levels, respectively [<xref rid="B47-nutrients-17-02804" ref-type="bibr">47</xref>]. These clinically paradoxical responses are of critical importance in populations with inherently elevated Lp(a) levels, as following population-wide recommendations for reducing SFA will have an opposite effect on Lp(a) levels [<xref rid="B47-nutrients-17-02804" ref-type="bibr">47</xref>].</p><p>Research has also revealed the positive impact of the ketogenic diet on Lp(a) concentration. In a crossover trial, a decrease in Lp(a) concentrations from 401 U/L at baseline to 286 U/L was noted after two weeks of following a ketogenic diet [<xref rid="B48-nutrients-17-02804" ref-type="bibr">48</xref>]. These findings suggest that diet does have an impact on Lp(a). However, the findings remain inconsistent. Further studies involving metabolomics and lipidomic analyses are required to evaluate how diet impacts Lp(a) levels.</p></sec><sec><title>MicroRNA and Non-Coding RNA</title><p>Non-coding RNAs (lncRNAs) and microRNAs (miRNAs) play a considerable role in controlling atherogenic plaque development. MicroRNAs destroy messenger RNA as the main post-transcriptional regulatory mechanism, which is employed to control gene expression levels. Thus, the expression levels of miRNAs define the pathophysiological basis for atherogenesis. For instance, high levels of miR-29, miR-100, miR-155, miR-199, miR-221, miR-363, miR-497, miR-508, mi-21, miR-34, miR-210, miR-146, and miR-181 have been detected in atherosclerotic coronary arteries, while miR-1273, miR-490, miR-24, and miR-1284 are scarce and present in low quantities [<xref rid="B49-nutrients-17-02804" ref-type="bibr">49</xref>].</p><p>A long-term high-fat diet (HFD) causes the upregulation of miR-142-3p, miR-142-5p, miR-21, miR-146a, and miR-146b and suppresses others such as miR-200b, miR-200c, and miR-122, reflecting broad alterations in adipose tissue metabolism [<xref rid="B50-nutrients-17-02804" ref-type="bibr">50</xref>].</p><p>The onset of atherosclerosis begins with endothelial dysfunction, which prompts an inflammatory process leading to foam cell formation. Furthermore, miR-10a has been shown to block <italic toggle="yes">GATA6/VCAM1</italic> signalling in endothelial cells (ECs), thereby protecting against atheroma. Teixeira et al. (2022) stated that miR-10a, miR-31, and miR-17-3p regulate inflammation and the expression of adhesion molecules in ECs, while miR-126, one of the most researched miRNAs, prevents atherosclerosis by reducing endothelial permeability and modifying the vascular endothelial growth factor (VEGF) pathway [<xref rid="B51-nutrients-17-02804" ref-type="bibr">51</xref>]. In cellular experiments, arachidonic acid (AA) increased the expression of anti-inflammatory microRNAs such as miR-10a, miR-17-3p, miR-125a, miR-155, and miR-181b in endothelial cells under basal conditions [<xref rid="B23-nutrients-17-02804" ref-type="bibr">23</xref>]. Also, endothelial activation is suppressed by miR-146a, which induces endothelial nitric oxide synthase (eNOS) synthesis, leading to reduced lipid uptake by macrophages, indicating its anti-atherogenic properties [<xref rid="B52-nutrients-17-02804" ref-type="bibr">52</xref>]. Docosahexaenoic acid (DHA) has been found to suppress miR-146a under inflammatory stimulation [<xref rid="B23-nutrients-17-02804" ref-type="bibr">23</xref>]. Research has shown that DHA supports an anti-inflammatory endothelial state, while AA exhibits more context-dependent effects, upregulating anti-inflammatory miRNAs under basal conditions but generally acting as a precursor to pro-inflammatory eicosanoids [<xref rid="B53-nutrients-17-02804" ref-type="bibr">53</xref>]. Variants in genes encoding the fatty acid desaturase enzymes FADS1 and FADS2 affect an individual&#8217;s ability to convert given precursors into AA, EPA, and DHA. For example, it has been suggested that the <italic toggle="yes">FADS1 rs174547</italic> polymorphism diminishes desaturase activity and therefore, the endogenous production of EPA and DHA. Due to the variation in the FADS genotype and dietary balance of &#969;-6 to &#969;-3 among individuals, personalized dietary recommendations can benefit such individuals [<xref rid="B53-nutrients-17-02804" ref-type="bibr">53</xref>].</p><p>Furthermore, improper synthesis and non-coding RNA activity affect atherosclerosis development [<xref rid="B54-nutrients-17-02804" ref-type="bibr">54</xref>]. There is a growing recognition that long non-coding RNA (lncRNA) contributes significantly to the atherosclerotic environment. In addition, it can activate or repress genes on a transcriptional and translational basis. Some long non-coding RNAs (LncRNAs) play a role in reducing senescence and DNA damage of atheroma plaques in pigs and humans [<xref rid="B54-nutrients-17-02804" ref-type="bibr">54</xref>].</p><p>Another significant molecule involved in the development of atherosclerosis is Antisense Non-Coding RNA in the <italic toggle="yes">INK4 Locus</italic> (<italic toggle="yes">ANRIL</italic>). The more severe the atherosclerosis, the higher the level of this molecule in the body. It is expressed in various cell types within the atherosclerotic plaque [<xref rid="B37-nutrients-17-02804" ref-type="bibr">37</xref>]. Circular ANRIL (<italic toggle="yes">circANRIL</italic>) has just been identified (<xref rid="nutrients-17-02804-f004" ref-type="fig">Figure 4</xref>) as different from its linear counterparts. Levels of <italic toggle="yes">circANRIL</italic> are inversely related to atherogenic status, and CircANRIL is located in smooth muscle cells, macrophages, and vascular tissue as an anti-atherogenic agent [<xref rid="B37-nutrients-17-02804" ref-type="bibr">37</xref>]. A study was conducted to assess the impact of a high-fat diet on LncRNAs in an atherosclerosis <italic toggle="yes">ApoE</italic>(&#8722;/&#8722;) mouse model [<xref rid="B55-nutrients-17-02804" ref-type="bibr">55</xref>]. It was found that 354 LncRNAs were affected by HFD, with 186 downregulated and 168 upregulated. These changes were consequently associated with inflammatory pathways in lipid metabolism and other vascular alterations, highlighting the role of diet in modulating LncRNA landscape [<xref rid="B55-nutrients-17-02804" ref-type="bibr">55</xref>].</p></sec></sec><sec id="sec3dot4dot2-nutrients-17-02804"><title>3.4.2. Microbiome-Associated Biomarkers</title><p>Health professionals and scientists have investigated how the microbiome impacts the development of atherosclerosis. The gut microbiome in people with atherosclerosis is different from that of healthy individuals, particularly with regard to the levels of <italic toggle="yes">Enterobacteriaceae</italic> and <italic toggle="yes">Streptococcus</italic> species, which tend to be higher in individuals with atherosclerosis. The gut microbiota produces vital molecules important for transport and metabolic functions that ensure a healthy cardiovascular system, and so differences in the microbiome can impact cardiovascular health, with some factors promoting atherosclerosis [<xref rid="B56-nutrients-17-02804" ref-type="bibr">56</xref>]. Gut bacteria metabolize food components, which means that different diets impact the gut metabolome. For example, Western dietary patterns rich in red meat, eggs, and dairy supply choline and L-carnitine, which produce trimethylamine (TMA) as the intestinal microbiota breaks down choline. On the other hand, diets rich in plant sterol esters and &#946;-glucan have been found to reduce TMA levels, consequently preventing atherosclerosis [<xref rid="B57-nutrients-17-02804" ref-type="bibr">57</xref>]. TMA can convert to trimethylamine-N-oxide (TMAO), an atherogenic substance produced by the liver. Atherosclerosis is facilitated by increased arterial inflammation and reactive platelet activity that can be promoted by TMAO [<xref rid="B57-nutrients-17-02804" ref-type="bibr">57</xref>].</p><p>In addition to TMAO, other pro-atherosclerotic compounds are also produced by Gram-negative bacteria and are represented by the molecular class known as lipopolysaccharides (LPS). LPS can promote numerous inflammatory reactions involved in atherosclerosis. Activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase by LPS leads to the release of reactive oxygen species (ROS). The stimulation by the gut microbiota produces secondary bile acids, which in turn trigger two important receptors: membrane-bound Takeda G protein-coupled receptor 5 (TGR5) and nuclear Farnesoid X receptor (FXR) [<xref rid="B57-nutrients-17-02804" ref-type="bibr">57</xref>]. These receptors have also been reported to reduce the rate of atherosclerosis progression via NF-&#954;B suppression that causes attenuation of pro-inflammatory cytokines production and inhibits cluster of differentiation (CD36) expression, thus reducing LDL absorption [<xref rid="B57-nutrients-17-02804" ref-type="bibr">57</xref>]. However, the gut microbiota produces short-chain fatty acids (SCFAs) like butyrate from the fermentation of dietary fibre, which has been shown to suppress the formation of atherosclerotic plaques. The potential of butyrate to improve plaque stability is derived from its ability to reduce ROS and nitric oxide release by macrophages and suppress the synthesis of well-established inflammatory molecules like matrix metalloproteinase-2, chemotaxis protein-1, and endothelial cell adhesion molecule-1. Therefore, consumption of a high-fibre diet is linked to increased levels of SCFAs (e.g., butyrate) [<xref rid="B57-nutrients-17-02804" ref-type="bibr">57</xref>].</p><p>In a recent study investigating the relationship between the gut microbiome of patients with atherosclerotic CVD and clinical characteristics, a random forest classifier was implemented for 405 atherosclerotic and control samples. The classifier demonstrated encouraging diagnostic potential with respect to an Area Under the Receiver Operating Curve (AUC) score that stands at 0.86 [<xref rid="B56-nutrients-17-02804" ref-type="bibr">56</xref>]. The classifier discovered significant bacteria, including <italic toggle="yes">Lachnospiraceae</italic>, <italic toggle="yes">Clostridium nexile</italic>, <italic toggle="yes">R. gnavus</italic>, <italic toggle="yes">A. parvulum</italic>, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">E. lenta</italic>, and <italic toggle="yes">L. salivarius</italic>. These findings suggest that gut microbiome characteristics connected to atherosclerosis can be used as non-invasive biomarkers.</p><p>Further probing showed that the classifier founded on microbial lipid genes (MLGs) performed better than the one founded exclusively on trimethylamine (TMA) lyases (AUC 0.63), indicating that atherosclerosis is due to multiple factors, not just TMAO [<xref rid="B56-nutrients-17-02804" ref-type="bibr">56</xref>,<xref rid="B58-nutrients-17-02804" ref-type="bibr">58</xref>]. Researchers found certain types of bacteria in high abundance in individuals with atherosclerosis, which encode for the enzyme choline-TMA lyase, among them <italic toggle="yes">S. anginosus</italic>, <italic toggle="yes">C. nexile</italic>, and unclassified <italic toggle="yes">Erysipelotrichaceae. E. aerogenes</italic> and <italic toggle="yes">Klebsiella pneumoniae</italic>, which are bacterial species with different genes encoding choline-TMA lyase and another more promiscuous types of TMA lyase.</p><p>Some bacteria are observed to exhibit virulence components, including immunogenic lipoprotein A (IlpA) and PhoP within the PhoQ/PhoP system, which can play a role in the development of atherosclerosis [<xref rid="B56-nutrients-17-02804" ref-type="bibr">56</xref>]. It is therefore important to understand the connection between the gut microbiome and distinct metabolic reactions to enable a transition to a more personalized mode of healthcare.</p></sec><sec id="sec3dot4dot3-nutrients-17-02804"><title>3.4.3. Metabolomic Biomarkers</title><p>The metabolomic approach assesses small molecule metabolites in biological samples that reflect the state of the system or the entire organism and offers additional insights into the pathology of the illness [<xref rid="B59-nutrients-17-02804" ref-type="bibr">59</xref>].</p><p>The application of metabolomic techniques has successfully unveiled evidence of risk factors associated with atherosclerosis. Research conducted on human tissues has identified metabolites and pathways that could be linked to atherosclerosis [<xref rid="B60-nutrients-17-02804" ref-type="bibr">60</xref>]. These metabolites provide insight into metabolic deregulation associated with augmented plaque formation in aortic tissue; for instance, sphingolipids, ceramides, and glycerophospholipids are some of the metabolites discussed in the literature. Atherosclerosis was characterized by variation in purine pathway-related metabolites, including phosphatidylethanolamine-ceramides (PE-Cer) and glucosylceramides (GlcCers) [<xref rid="B61-nutrients-17-02804" ref-type="bibr">61</xref>].</p><p>Two pathways known to participate in the development of atherosclerosis, namely ceramide and cholesterol, may share different lipids with previously unknown links to atherogenesis, specifically phosphatidylethanolamine-ceramides (PE-Cers) [<xref rid="B61-nutrients-17-02804" ref-type="bibr">61</xref>]. Lipidomic analysis of atherosclerotic plaques has revealed significant accumulation of PE-Cers, indicating their importance in sphingolipid and sterol metabolism. Functionally, PE-Cer performs a dual role, i.e., it affects the membrane structure by altering lateral cholesterol organization and modulates the pro-inflammatory signalling cascade. This dual influence on both membrane architecture and intracellular signalling positions PE-Cer as a mechanistic bridge between ceramide-driven stress responses and cholesterol-driven lipid accumulation [<xref rid="B61-nutrients-17-02804" ref-type="bibr">61</xref>,<xref rid="B62-nutrients-17-02804" ref-type="bibr">62</xref>].</p><p>Glycosphingolipids (glucosylceramide and lactosylceramide), which are derived from ceramides, are reported to be present in high levels in human atherosclerotic plaques and are pro-inflammatory [<xref rid="B63-nutrients-17-02804" ref-type="bibr">63</xref>]. Lactosylceramide and ceramide induce cell apoptosis through neutral sphingomyelinase. Lactosylceramide has also been suggested to promote plaque formation. It upregulates the adhesion molecules on vSMCs and vascular endothelial cells and activates neutrophils, thereby facilitating plaque inflammation [<xref rid="B63-nutrients-17-02804" ref-type="bibr">63</xref>].</p><p>The conversion of GlcCers, which are glycosphingolipids, from Cer to lactosylceramides (<xref rid="nutrients-17-02804-f005" ref-type="fig">Figure 5</xref>) is part of a mechanism that causes cell division, which is triggered by oxidized low-density lipoproteins [<xref rid="B61-nutrients-17-02804" ref-type="bibr">61</xref>]. Unusual buildup of glycosphingolipids, particularly GlcCers, has been found in atheromas in the human aorta. In the course of atherogenesis, increased oxidative low-density lipoproteins (LDL) may, in turn, raise GlcCers, leading to inflammation, thus worsening the condition [<xref rid="B64-nutrients-17-02804" ref-type="bibr">64</xref>].</p><p>Diet plays a significant role in modulating sphingolipid metabolism and atherosclerosis risk. Research using experimental models has shown that trans fats from the diet are incorporated into sphingolipids via the serine palmitoyltransferase pathway, leading to the formation of ceramides and glycosphingolipids [<xref rid="B65-nutrients-17-02804" ref-type="bibr">65</xref>]. Dietary trans-fat intake promotes the production and secretion of sphingolipids and very-low-density lipoproteins (VLDL), accelerating plaque formation compared to the results for diets rich in unsaturated fats [<xref rid="B65-nutrients-17-02804" ref-type="bibr">65</xref>].</p></sec></sec><sec id="sec3dot5-nutrients-17-02804"><title>3.5. Navigating Personalized Nutrition Approaches: Tailoring Strategies for Atherosclerosis Management</title><p>Over the years, international associations have provided scientifically proven nutrition advice to manage risk factors for atherosclerosis and CVDs. Despite these efforts, residual risk remains due to variability across studies and statistical approaches [<xref rid="B66-nutrients-17-02804" ref-type="bibr">66</xref>]. Notable differences exist between the AHA and ESC guidelines: the AHA provides detailed recommendations regarding specific foods and quantities, while the ESC focuses on nutrient-based targets [<xref rid="B67-nutrients-17-02804" ref-type="bibr">67</xref>]. Ideally, clinical guidelines should be grounded in multiple RCTs, but evidence remains limited. An assessment revealed that only 10% of ACC/AHA and 15% of ESC guidelines are supported by high-quality RCTs [<xref rid="B68-nutrients-17-02804" ref-type="bibr">68</xref>]. Similarly, the NICE relies on older RCTs for fibre intake recommendations, while the ESC incorporates meta-analyses up to the 2010s [<xref rid="B69-nutrients-17-02804" ref-type="bibr">69</xref>]. For saturated fat, the ESC relies on modelling data, whereas the AHA does not specifically mention atherosclerosis [<xref rid="B12-nutrients-17-02804" ref-type="bibr">12</xref>].</p><p>This limits the ability of health practitioners to provide precise clinical recommendations to patients due to a lack of consensus regarding available data and comprehensive nutrition recommendations. At present, the prevention of atherosclerosis requires dietary guidance developed through assessing epidemiologic and interventional research to arrive at a consensual guideline based on the quality of the evidence [<xref rid="B67-nutrients-17-02804" ref-type="bibr">67</xref>].</p><p>At an individual level, population-based nutrition guidance might not always work efficiently. Genetic predispositions, metabolic phenotype, health condition, lifestyle choices, and life events of each patient will determine whether some food elements should be enhanced, reduced, or eliminated to optimize one&#8217;s risk profile [<xref rid="B70-nutrients-17-02804" ref-type="bibr">70</xref>,<xref rid="B71-nutrients-17-02804" ref-type="bibr">71</xref>,<xref rid="B72-nutrients-17-02804" ref-type="bibr">72</xref>]. Atherosclerosis is a disease whose course is driven by the inflammation-related genes, the production of foam cells, the accumulation of cholesterol by macrophages, and cholesterol metabolism [<xref rid="B73-nutrients-17-02804" ref-type="bibr">73</xref>]. Food components directly or indirectly influence various forms of genome behaviour (genes and proteins) [<xref rid="B21-nutrients-17-02804" ref-type="bibr">21</xref>,<xref rid="B74-nutrients-17-02804" ref-type="bibr">74</xref>]. Thus, each person&#8217;s genetic constitution can determine the overall health effects of consuming a particular diet.</p><p>It has been observed that some foods exhibit epigenetic changes via actions of the short non-coding RNA molecules, histone acetylation/deacetylation processes, and DNA methylation (methionine, folic acid, B vitamins) [<xref rid="B75-nutrients-17-02804" ref-type="bibr">75</xref>]. It is reported that increased levels of homocysteine in the blood are related to higher DNA methylation levels, offering additional evidence of genetic influence on the methylation patterns that may play a role in atherosclerosis progression. The long interspersed nuclear element-1 (LINE-1) methylation was 0.05 (0.01, 0.13) 5 mC higher for every 3 mmol/L increase in homocysteine [<xref rid="B20-nutrients-17-02804" ref-type="bibr">20</xref>]. Previous research findings in mouse models indicate a relationship between hypomethylated DNA and reduced methylenetetrahydrofolate reductase (MTHFR) and DNA methyltransferase (DNMT) gene expression during atherosclerosis development phases [<xref rid="B76-nutrients-17-02804" ref-type="bibr">76</xref>,<xref rid="B77-nutrients-17-02804" ref-type="bibr">77</xref>]. These other two genes, whose activity partially depends on DNA methylation, are associated with the initial development of atherosclerosis.</p><p>Moreover, studies have also shown that individuals with the CC genotype of apolipoprotein A2 (<italic toggle="yes">APOA2</italic>) rs5082 polymorphism in the gene promoter region exhibit a significantly larger body mass index (BMI) than those with the TT genotype, consuming diets rich in saturated fats [<xref rid="B78-nutrients-17-02804" ref-type="bibr">78</xref>]. Similarly, recent research indicates that the same gene&#8211;nutrient interaction may lead to higher levels of low-density lipoprotein cholesterol (LDL-C) and increased LDL-C/HDL-C ratio among diseased subjects. Consequently, a low-SFA diet will benefit people with the CC genotype for the <italic toggle="yes">APOA2</italic> SNP, thus preventing them from becoming obese and developing hypercholesteremia [<xref rid="B78-nutrients-17-02804" ref-type="bibr">78</xref>,<xref rid="B79-nutrients-17-02804" ref-type="bibr">79</xref>].</p><p>Even though these studies focused on individual macronutrients, dietary pattern comparisons are becoming increasingly common to account for the synergistic effect of meals. Two groups were created for the 12-month Coronary Diet Intervention with Olive Oil and Cardiovascular Prevention (CORDIOPREV) intervention trial. One group adhered to a Mediterranean diet with 35% fat content, consisting of 22% monounsaturated fatty acid, while another group was placed on a &#8216;low-fat&#8217; diet containing 8% fat and 12% monounsaturated fatty acid [<xref rid="B18-nutrients-17-02804" ref-type="bibr">18</xref>,<xref rid="B80-nutrients-17-02804" ref-type="bibr">80</xref>]. The research showed that in the study sample, the TG levels of those with the T allele of the APOE gene were lower than the levels in those with the TG genotype. A higher level of HDL-C was observed in people with the T allele than in those without it. Research findings have shown why individuals respond differently to similar diets by indicating interactions between genetics and food [<xref rid="B80-nutrients-17-02804" ref-type="bibr">80</xref>]. Another study was conducted to determine whether there were effects of the Mediterranean diet on telomere lengths in persons at high cardiovascular risk, determining that the pro12Ala variant in the PPAR&#947;2 gene (rs1801282) was associated with better maintenance of telomere lengths for people following the Mediterranean diet [<xref rid="B22-nutrients-17-02804" ref-type="bibr">22</xref>]. In the CORDIOPREV study, CLOCK gene variants were associated with the Mediterranean diet in patients with coronary heart disease (CHD). Individuals harbouring polymorphic rs4580704 CLOCK genes displayed better inflammation markers and lipid profiles when they adhered to the Mediterranean diet [<xref rid="B23-nutrients-17-02804" ref-type="bibr">23</xref>].</p><p>Previous cases using SNP examinations showed that there are diet&#8211;gene interactions. Some of this research explored the interaction of omega-3 fatty acids and fish oil supplementation with SNP in <italic toggle="yes">PLA2</italic>, <italic toggle="yes">MGLL</italic>, <italic toggle="yes">IQCJ</italic>, <italic toggle="yes">NXPH1</italic>, <italic toggle="yes">PHF17</italic>, and <italic toggle="yes">MYB</italic> genes and found that variations in these genes influence TG levels in plasma post-supplementation [<xref rid="B27-nutrients-17-02804" ref-type="bibr">27</xref>]. Nevertheless, the pathophysiology of risk factors such as obesity and dyslipidaemia is most likely polygenic and intricate [<xref rid="B81-nutrients-17-02804" ref-type="bibr">81</xref>]. Individuals are awarded scores using the Genetic Risk Score (GRS) method, depending on the count of risk alleles and the trait under consideration. Those in the high-risk group (with a score greater than 7) displayed a 1.94 cm larger waist circumference and BMIs averaging 0.93 kg/m<sup>2</sup>, approximately 1.69% higher relative to the results for low-risk individuals (with a score = 7), in addition to higher body fat index values [<xref rid="B79-nutrients-17-02804" ref-type="bibr">79</xref>].</p><p>Additionally, there were observed anomalies within certain dietary areas when comparing both clusters based on their rates, including a greater number of cases involving acute myocardial infarction among those at higher risks, as opposed to those with lower chances who consumed polyunsaturated fatty acids (PUFAs). These prediction algorithms may serve as the basis of stratification, allowing high-risk individuals to alter their food intake based on their genotype. For instance, a 31-SNP GRS was developed using imputation from the 1000 Genomes Project database for predicting non-responsiveness to omega-3 PUFA treatment aimed at reducing TG levels [<xref rid="B19-nutrients-17-02804" ref-type="bibr">19</xref>,<xref rid="B79-nutrients-17-02804" ref-type="bibr">79</xref>,<xref rid="B82-nutrients-17-02804" ref-type="bibr">82</xref>]. Also, genetic risk scores (GRS) accounted for almost 50% of the difference in TG response to omega-3 supplementation, highlighting the importance of genetic predisposition in personalized omega-3 interventions in atherosclerosis management [<xref rid="B21-nutrients-17-02804" ref-type="bibr">21</xref>]. Research has also shown that by substituting SFAs with PUFAs, peripheral blood mononuclear cells showed a downregulation of uncoupling protein 2 (<italic toggle="yes">UCP2</italic>) and peroxisome proliferator-activated receptor delta (<italic toggle="yes">PPARD</italic>) genes, which are implicated in inflammation [<xref rid="B25-nutrients-17-02804" ref-type="bibr">25</xref>].</p><p>Chromatin is a nucleosome made up of histones and the DNA fragments that wrap around them. Changing the DNA strand&#8217;s ability to be transcribed requires the addition of acetylation, methylation, phosphorylation, and ubiquitination chemicals at the histone tail [<xref rid="B83-nutrients-17-02804" ref-type="bibr">83</xref>]. Histone acetylation, for instance, can unravel the chromatin and open the DNA for transcription, generally leading to gene expression. However, bioactive curcumin protects the heart by blocking the acetylation of particular histones, turning off genes that promote vascular inflammation, like <italic toggle="yes">TREM-1</italic>, in CVDs [<xref rid="B84-nutrients-17-02804" ref-type="bibr">84</xref>]. The reason for mRNA degradation and inhibition of mRNAs translation into proteins is the binding of microRNAs (miRNAs) to messenger RNAs, referred to as non-coding RNAs. An example is when omega-3 PUFAs regulate microRNA quantity that control lipid metabolism genes [<xref rid="B50-nutrients-17-02804" ref-type="bibr">50</xref>]. It has been shown that omega-3 (<italic toggle="yes">n</italic>-3-PUFA) and arachidonic acid (<italic toggle="yes">n</italic>-6-PUFA) supplementation affects miRNA expression in endothelial and monocyte/macrophage cell lines, thus influencing vascular inflammation [<xref rid="B23-nutrients-17-02804" ref-type="bibr">23</xref>].</p></sec><sec id="sec3dot6-nutrients-17-02804"><title>3.6. Personalized Nutrition in Clinical Settings: Opportunities and Challenges</title><p>Healthcare professionals can combine population-based advice with personalized nutrition strategies to devise food-oriented plans to maximize benefits and minimize risks for each individual. This can include providing specific dietary advice based on knowledge of different molecular mechanisms affected by other variables like microbiota or epigenetic factors, in addition to new genetic variations, and closely watching any responses following food intake [<xref rid="B85-nutrients-17-02804" ref-type="bibr">85</xref>]. Healthcare professionals can use personalized nutrition strategies to identify patients with high blood pressure who possess certain gut bacterial species or epigenetic markers that indicate they are sensitive to dietary salt [<xref rid="B86-nutrients-17-02804" ref-type="bibr">86</xref>]. Consequently, the appropriate dietary plans will be uniquely proposed for each patient, improving the treatment&#8217;s outcome and efficiency. Therefore, health practitioners can turn general dietary advice into more tailored therapies through personalized nutrition approaches.</p><p>Epigenetic studies involving diet treatment are uncommon and usually focus on DNA methylation, with histone modifications and miRNAs in cellular or animal models being the most studied pathways [<xref rid="B87-nutrients-17-02804" ref-type="bibr">87</xref>]. More research is needed to show how certain diets can lead to gene changes predisposing individuals to atherosclerosis. However, this is challenging due to the fact that some of these markers change over time. Furthermore, as epigenetic marks are often tissue-specific, it is necessary to employ oral or blood cells as markers of epigenetic processes in tissues that are difficult to reach. Diverse sequencing approaches are essential when dealing with various epigenetic markers (i.e., DNA, RNA, proteins), making this process relatively complicated and costly [<xref rid="B87-nutrients-17-02804" ref-type="bibr">87</xref>]. As a result, the current drawbacks of epigenomics limit its immediate potential to contribute to a precise nutrition strategy for atherosclerosis prevention.</p><p>The practical application of nutrigenomic methods in clinical and biological research is associated with several problems. The AHA scientific statement sheds light on several challenges and limitations, particularly in setting up and conducting randomized clinical trials that can offer a firm basis of information for patient consultations [<xref rid="B88-nutrients-17-02804" ref-type="bibr">88</xref>]. Among the main disadvantages of nutrigenomic clinical trials is that controlling subjects&#8217; meals becomes extremely challenging. This issue might be partially solved by identifying specific biomarkers related to food consumption, allowing us to determine whether eating habits are related to abnormalities. Furthermore, actual problems with regulation occur, especially when fixing terminology in clinical practice and nutrigenomics/nutrigenetics studies. For instance, in the postgenomic era, the gene (as the unit of heredity) has been modified so that now it means more than just a DNA sequence but also includes the way chromosomes are organized and the way that other non-DNA macromolecules contribute to epigenetic regulation [<xref rid="B89-nutrients-17-02804" ref-type="bibr">89</xref>]. Many ethical, legal, and societal obstacles exist in regards to protecting nutrigenomic information and ensuring that marginalized countries have equitable access to nutritional resources [<xref rid="B90-nutrients-17-02804" ref-type="bibr">90</xref>].</p><p>Given the current challenges and limitations, the most effective strategies for integrating nutrigenomics into healthcare systems remain uncertain. However, one potential application could involve physicians recommending personalized diets for patients with non-communicable diseases. A recent literature review has supported the efficiency of the Mediterranean diet in protecting against heart disease. Moreover, while the Mediterranean diet is seen as part of the solution to the current high rate of non-communicable diseases, it is not a replacement for creating personalized nutrition programs [<xref rid="B91-nutrients-17-02804" ref-type="bibr">91</xref>].</p><p>Achieving personalized nutrition requires integrating nutrition into nutrigenomics and nutrigenetics into medicine. This requires scientific research and clinical studies, including randomized clinical trials, to create a strong foundation of knowledge that will enable clinicians to counsel patients effectively [<xref rid="B85-nutrients-17-02804" ref-type="bibr">85</xref>]. Customized nutrition professional development is also important, as is creating counselling therapeutic principles that inform evidence-based practices [<xref rid="B85-nutrients-17-02804" ref-type="bibr">85</xref>].</p><p>A potential limitation of this review is the restriction to studies published within the last ten years. While this approach ensures the inclusion of the most recent evidence and advancements in personalized nutrition and omics-based interventions for atherosclerosis, it may have excluded relevant earlier foundational studies. Moreover, our review highlighted inter-individual variability in gene&#8211;diet interactions. However, subgroup analyses by sex and age were not consistently available across the included studies. As a result, our review did not stratify outcomes by these demographic factors.</p></sec></sec><sec sec-type="conclusions" id="sec4-nutrients-17-02804"><title>4. Conclusions and Future Directions</title><p>Intervention guidelines provided by the AHA, ESC, and NICE are globally recognized for treating atherosclerosis and emphasize dietary habits and physical activity. These guidelines generally agree on the need to decrease the consumption of saturated fats, sugars, and sodium, while increasing the consumption of fruits, vegetables, whole grains, and good fats. Experimental data, including clinical studies, strongly support these guidelines, but they need to be updated and revised periodically due to the diversity of recommendations and the dynamic nature of dietary research.</p><p>The findings of this review suggest that following Mediterranean and low-fat diets consistently improves lipid profiles, reduces systemic inflammation, and supports vascular health. Specific nutrient strategies, such as increasing omega-3 polyunsaturated fatty acids and lowering saturated fat intake, further help lower cardiovascular risk. Importantly, the effectiveness of these dietary interventions is influenced by inter-individual variability, including genetic predispositions, gut microbiome composition, and metabolomic signatures. Factors like genetic background, gut microbiome composition, and metabolic profiles play a role. Therefore, while general dietary guidelines offer a strong foundation, using personalized nutrition approaches allows us to tailor prevention strategies more effectively, maximizing their impact on reducing atherosclerosis risk.</p><p>Even though personalized nutrition is still in its infancy, some outcomes have been implemented into mainstream medicine, particularly in the nutrigenetics sector. The substantial amount of data supporting a genetic-based strategy necessitates further advances in this area. The application of nutrigenomics in practice is hampered by some specific factors, including dietitians&#8217; attitudes towards genetic tests and the absence of personalized nutrition education in medical programs aimed at health specialists. The personalized nutrition model relies upon synergistic collaboration among different players within the system, making adoption slow.</p><p>Nutrition experts need to adopt innovative diagnosis and monitoring techniques, while policymakers should develop appropriate strategies to protect personal data obtained through extensive data analysis. Private industries also possess significant responsibilities to ensure that personalized nutrition can be effectively translated and incorporated into public nutrition practices. In its position paper, the International Society of Nutrigenetics and Nutrigenomics emphasizes the critical need to address ethical and legal considerations when introducing personalized nutrition into society. These considerations should include issues related to equity, environmental factors, the interplay between genetics and food choices, individual gene&#8211;lifestyle interactions, and the influence of the microbiome. This is particularly important for CVDs, and atherosclerosis in particular, where there is clear evidence that dietary interventions are critical for both its prevention and treatment.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-nutrients-17-02804"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/nu17172804/s1">https://www.mdpi.com/article/10.3390/nu17172804/s1</uri>. Table S1: PRISMA Checklist for drafting a systematic review on Personalized Nutrition Biomarkers and Dietary Strategies for Atherosclerosis Risk Management. Table S2: Evaluation of Gene&#8211;Diet Interaction Studies Using the Boffetta et al. Framework. Figure S1: Traffic light plot for non-randomized observational studies [<xref rid="B17-nutrients-17-02804" ref-type="bibr">17</xref>,<xref rid="B20-nutrients-17-02804" ref-type="bibr">20</xref>,<xref rid="B21-nutrients-17-02804" ref-type="bibr">21</xref>,<xref rid="B26-nutrients-17-02804" ref-type="bibr">26</xref>]. Figure S2: Traffic light plot for randomized controlled trial [<xref rid="B18-nutrients-17-02804" ref-type="bibr">18</xref>,<xref rid="B22-nutrients-17-02804" ref-type="bibr">22</xref>,<xref rid="B24-nutrients-17-02804" ref-type="bibr">24</xref>,<xref rid="B25-nutrients-17-02804" ref-type="bibr">25</xref>]. Figure S3: Traffic light plot for non-randomized interventional studies [<xref rid="B19-nutrients-17-02804" ref-type="bibr">19</xref>,<xref rid="B27-nutrients-17-02804" ref-type="bibr">27</xref>,<xref rid="B28-nutrients-17-02804" ref-type="bibr">28</xref>,<xref rid="B29-nutrients-17-02804" ref-type="bibr">29</xref>].</p><supplementary-material id="nutrients-17-02804-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nutrients-17-02804-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, C.J.B. and N.K.; methodology, K.F.; software, K.F.; validation, F.A., M.S.u.D. and H.B.; formal analysis, K.F.; investigation, F.A.; resources, C.J.B.; data curation, M.S.u.D.; writing&#8212;original draft preparation, K.F.; writing&#8212;review and editing, K.F., M.S.u.D. and F.A.; visualization, F.A.; supervision, N.K.; project administration, N.K.; funding acquisition, C.J.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data is available upon request from the authors.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-nutrients-17-02804"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussain</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Rafi</surname><given-names>U.</given-names></name><name name-style="western"><surname>Imran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>M.U.</given-names></name><name name-style="western"><surname>Abbas</surname><given-names>S.K.</given-names></name></person-group><article-title>Risk Factors Associated with Cardiovascular Disorders: Risk Factors Associated with Cardiovascular Disorders</article-title><source>Pak. Biomed. J.</source><year>2024</year><volume>7</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.54393/pbmj.v7i02.1034</pub-id></element-citation></ref><ref id="B2-nutrients-17-02804"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ware</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Maposa</surname><given-names>I.</given-names></name><name name-style="western"><surname>Flood</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brant</surname><given-names>L.C.C.</given-names></name><name name-style="western"><surname>Khandelwal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jessen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Perman</surname><given-names>G.</given-names></name></person-group><article-title>Comparison of Cardiovascular Health Profiles Across Population Surveys From 5 High-to Low-Income Countries</article-title><source>CJC Open</source><year>2024</year><volume>6</volume><fpage>582</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/j.cjco.2023.11.021</pub-id><pub-id pub-id-type="pmid">38559335</pub-id><pub-id pub-id-type="pmcid">PMC10980894</pub-id></element-citation></ref><ref id="B3-nutrients-17-02804"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name></person-group><article-title>Matrix Stiffness, Endothelial Dysfunction and Atherosclerosis</article-title><source>Mol. Biol. Rep.</source><year>2023</year><volume>50</volume><fpage>7027</fpage><lpage>7041</lpage><pub-id pub-id-type="doi">10.1007/s11033-023-08502-5</pub-id><pub-id pub-id-type="pmid">37382775</pub-id></element-citation></ref><ref id="B4-nutrients-17-02804"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nedkoff</surname><given-names>L.</given-names></name><name name-style="western"><surname>Briffa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zemedikun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Herrington</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>F.L.</given-names></name></person-group><article-title>Global Trends in Atherosclerotic Cardiovascular Disease</article-title><source>Clin. Ther.</source><year>2023</year><volume>45</volume><fpage>1087</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2023.09.020</pub-id><pub-id pub-id-type="pmid">37914585</pub-id></element-citation></ref><ref id="B5-nutrients-17-02804"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Eckardstein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nordestgaard</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Remaley</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Catapano</surname><given-names>A.L.</given-names></name></person-group><article-title>High-Density Lipoprotein Revisited: Biological Functions and Clinical Relevance</article-title><source>Eur. Heart J.</source><year>2023</year><volume>44</volume><fpage>1394</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehac605</pub-id><pub-id pub-id-type="pmid">36337032</pub-id><pub-id pub-id-type="pmcid">PMC10119031</pub-id></element-citation></ref><ref id="B6-nutrients-17-02804"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bj&#246;rkegren</surname><given-names>J.L.M.</given-names></name><name name-style="western"><surname>Lusis</surname><given-names>A.J.</given-names></name></person-group><article-title>Atherosclerosis: Recent Developments</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>1630</fpage><lpage>1645</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.04.004</pub-id><pub-id pub-id-type="pmid">35504280</pub-id><pub-id pub-id-type="pmcid">PMC9119695</pub-id></element-citation></ref><ref id="B7-nutrients-17-02804"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamzolas</surname><given-names>O.</given-names></name><name name-style="western"><surname>Papazoglou</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Gemousakakis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moysidis</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Kyriakoulis</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Brilakis</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Milkas</surname><given-names>A.</given-names></name></person-group><article-title>Concomitant Coronary Artery Disease in Identical Twins: Case Report and Systematic Literature Review</article-title><source>J. Clin. Med.</source><year>2023</year><volume>12</volume><elocation-id>5742</elocation-id><pub-id pub-id-type="doi">10.3390/jcm12175742</pub-id><pub-id pub-id-type="pmid">37685809</pub-id><pub-id pub-id-type="pmcid">PMC10489011</pub-id></element-citation></ref><ref id="B8-nutrients-17-02804"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kawashiri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nohara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sekiya</surname><given-names>T.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Takamura</surname><given-names>M.</given-names></name></person-group><article-title>Genetic Counseling and Genetic Testing for Familial Hypercholesterolemia</article-title><source>Genes</source><year>2024</year><volume>15</volume><elocation-id>297</elocation-id><pub-id pub-id-type="doi">10.3390/genes15030297</pub-id><pub-id pub-id-type="pmid">38540356</pub-id><pub-id pub-id-type="pmcid">PMC10970256</pub-id></element-citation></ref><ref id="B9-nutrients-17-02804"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>B.</given-names></name></person-group><article-title>The Gut Microbiota-Artery Axis: A Bridge between Dietary Lipids and Atherosclerosis?</article-title><source>Prog. Lipid Res.</source><year>2023</year><volume>89</volume><fpage>101209</fpage><pub-id pub-id-type="doi">10.1016/j.plipres.2022.101209</pub-id><pub-id pub-id-type="pmid">36473673</pub-id></element-citation></ref><ref id="B10-nutrients-17-02804"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faghy</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Yates</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hills</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Jayasinghe</surname><given-names>S.</given-names></name><name name-style="western"><surname>da Luz Goulart</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arena</surname><given-names>R.</given-names></name><name name-style="western"><surname>Laddu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gururaj</surname><given-names>R.</given-names></name><name name-style="western"><surname>Veluswamy</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>S.</given-names></name></person-group><article-title>Cardiovascular Disease Prevention and Management in the COVID-19 Era and beyond: An International Perspective</article-title><source>Prog. Cardiovasc. Dis.</source><year>2023</year><volume>76</volume><fpage>102</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.pcad.2023.01.004</pub-id><pub-id pub-id-type="pmid">36693488</pub-id><pub-id pub-id-type="pmcid">PMC9862672</pub-id></element-citation></ref><ref id="B11-nutrients-17-02804"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>N.</given-names></name><name name-style="western"><surname>Guevara-Cruz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vel&#225;zquez-Villegas</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Tovar</surname><given-names>A.R.</given-names></name></person-group><article-title>Nutrition and Atherosclerosis</article-title><source>Arch. Med. Res.</source><year>2015</year><volume>46</volume><fpage>408</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2015.05.010</pub-id><pub-id pub-id-type="pmid">26031780</pub-id></element-citation></ref><ref id="B12-nutrients-17-02804"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Manmathan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>P.</given-names></name></person-group><article-title>Primary Prevention of Cardiovascular Disease: A Review of Contemporary Guidance and Literature</article-title><source>JRSM Cardiovasc. Dis.</source><year>2017</year><volume>6</volume><fpage>2048004016687211</fpage><pub-id pub-id-type="doi">10.1177/2048004016687211</pub-id><pub-id pub-id-type="pmid">28286646</pub-id><pub-id pub-id-type="pmcid">PMC5331469</pub-id></element-citation></ref><ref id="B13-nutrients-17-02804"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bush</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Blumberg</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>El-Sohemy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Minich</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Ordov&#225;s</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Behm</surname><given-names>V.A.Y.</given-names></name></person-group><article-title>Toward the Definition of Personalized Nutrition: A Proposal by the American Nutrition Association</article-title><source>J. Am. Coll. Nutr.</source><year>2020</year><volume>39</volume><fpage>5</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1080/07315724.2019.1685332</pub-id><pub-id pub-id-type="pmid">31855126</pub-id></element-citation></ref><ref id="B14-nutrients-17-02804"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matusheski</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Caffrey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mezgec</surname><given-names>S.</given-names></name><name name-style="western"><surname>Surendran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hjorth</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>McNulty</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pentieva</surname><given-names>K.</given-names></name><name name-style="western"><surname>Roager</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Seljak</surname><given-names>B.K.</given-names></name><etal/></person-group><article-title>Diets, nutrients, genes and the microbiome: Recent advances in personalised nutrition</article-title><source>Br. J. Nutr.</source><year>2021</year><volume>126</volume><fpage>1489</fpage><lpage>1497</lpage><pub-id pub-id-type="doi">10.1017/S0007114521000374</pub-id><pub-id pub-id-type="pmid">33509307</pub-id><pub-id pub-id-type="pmcid">PMC8524424</pub-id></element-citation></ref><ref id="B15-nutrients-17-02804"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>Effect of chrono-nutrition&#8211;based dietary intervention on metabolic disease</article-title><source>Precis. Nutr.</source><year>2024</year><volume>3</volume><fpage>e00076</fpage></element-citation></ref><ref id="B16-nutrients-17-02804"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waffenschmidt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Knelangen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sieben</surname><given-names>W.</given-names></name><name name-style="western"><surname>B&#252;hn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pieper</surname><given-names>D.</given-names></name></person-group><article-title>Single Screening versus Conventional Double Screening for Study Selection in Systematic Reviews: A Methodological Systematic Review</article-title><source>BMC Med. Res. Methodol.</source><year>2019</year><volume>19</volume><elocation-id>132</elocation-id><pub-id pub-id-type="doi">10.1186/s12874-019-0782-0</pub-id><pub-id pub-id-type="pmid">31253092</pub-id><pub-id pub-id-type="pmcid">PMC6599339</pub-id></element-citation></ref><ref id="B17-nutrients-17-02804"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valsesia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Egli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bosco</surname><given-names>N.</given-names></name><name name-style="western"><surname>Magkos</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Goh</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Weiting</surname><given-names>H.</given-names></name><name name-style="western"><surname>Arigoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Leow</surname><given-names>M.K.-S.</given-names></name><etal/></person-group><article-title>Clinical- and Omics-Based Models of Subclinical Atherosclerosis in Healthy Chinese Adults: A Cross-Sectional Exploratory Study</article-title><source>Am. J. Clin. Nutr.</source><year>2021</year><volume>114</volume><fpage>1752</fpage><lpage>1762</lpage><pub-id pub-id-type="doi">10.1093/ajcn/nqab269</pub-id><pub-id pub-id-type="pmid">34476468</pub-id></element-citation></ref><ref id="B18-nutrients-17-02804"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-Delgado</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alcala-Diaz</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Leon-Acu&#241;a</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lopez-Moreno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Delgado-Lista</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gomez-Marin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Roncero-Ramos</surname><given-names>I.</given-names></name><name name-style="western"><surname>Yubero-Serrano</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Rangel-Zu&#241;iga</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Vals-Delgado</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Apolipoprotein E Genetic Variants Interact with Mediterranean Diet to Modulate Postprandial Hypertriglyceridemia in Coronary Heart Disease Patients: CORDIOPREV Study</article-title><source>Eur. J. Clin. Investig.</source><year>2019</year><volume>49</volume><fpage>e13146</fpage><pub-id pub-id-type="doi">10.1111/eci.13146</pub-id><pub-id pub-id-type="pmid">31166609</pub-id></element-citation></ref><ref id="B19-nutrients-17-02804"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marcotte</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Gu&#233;nard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lemieux</surname><given-names>S.</given-names></name><name name-style="western"><surname>Couture</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rudkowska</surname><given-names>I.</given-names></name><name name-style="western"><surname>Calder</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Minihane</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Vohl</surname><given-names>M.-C.</given-names></name></person-group><article-title>Fine Mapping of Genome-Wide Association Study Signals to Identify Genetic Markers of the Plasma Triglyceride Response to an Omega-3 Fatty Acid Supplementation</article-title><source>Am. J. Clin. Nutr.</source><year>2019</year><volume>109</volume><fpage>176</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1093/ajcn/nqy298</pub-id><pub-id pub-id-type="pmid">30624603</pub-id><pub-id pub-id-type="pmcid">PMC6358031</pub-id></element-citation></ref><ref id="B20-nutrients-17-02804"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Villamor</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shroff</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Nettleton</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Pilsner</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Diez-Roux</surname><given-names>A.V.</given-names></name></person-group><article-title>Dietary Intake, Plasma Homocysteine, and Repetitive Element DNA Methylation in the Multi-Ethnic Study of Atherosclerosis (MESA)</article-title><source>Nutr. Metab. Cardiovasc. Dis.</source><year>2014</year><volume>24</volume><fpage>614</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/j.numecd.2013.11.011</pub-id><pub-id pub-id-type="pmid">24477006</pub-id><pub-id pub-id-type="pmcid">PMC4037331</pub-id></element-citation></ref><ref id="B21-nutrients-17-02804"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kubow</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>D.E.</given-names></name></person-group><article-title>Common Variants in the CD36 Gene Are Associated with Dietary Fat Intake, High-Fat Food Consumption and Serum Triglycerides in a Cohort of Quebec Adults</article-title><source>Int. J. Obes.</source><year>2021</year><volume>45</volume><fpage>1193</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1038/s41366-021-00766-w</pub-id><pub-id pub-id-type="pmid">33574567</pub-id></element-citation></ref><ref id="B22-nutrients-17-02804"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Calz&#243;n</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Gonz&#225;lez</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Razquin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corella</surname><given-names>D.</given-names></name><name name-style="western"><surname>Salas-Salvad&#243;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Zalba</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marti</surname><given-names>A.</given-names></name></person-group><article-title>Pro12Ala Polymorphism of the PPAR&#947;2 Gene Interacts with a Mediterranean Diet to Prevent Telomere Shortening in the PREDIMED-NAVARRA Randomized Trial</article-title><source>Circ. Cardiovasc. Genet.</source><year>2015</year><volume>8</volume><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1161/CIRCGENETICS.114.000635</pub-id><pub-id pub-id-type="pmid">25406242</pub-id></element-citation></ref><ref id="B23-nutrients-17-02804"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roessler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kuhlmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hellwing</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leimert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schumann</surname><given-names>J.</given-names></name></person-group><article-title>Impact of Polyunsaturated Fatty Acids on MiRNA Profiles of Monocytes/Macrophages and Endothelial Cells&#8212;A Pilot Study</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>284</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18020284</pub-id><pub-id pub-id-type="pmid">28134837</pub-id><pub-id pub-id-type="pmcid">PMC5343820</pub-id></element-citation></ref><ref id="B24-nutrients-17-02804"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-Delgado</surname><given-names>F.</given-names></name><name name-style="western"><surname>Garcia-Rios</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alcala-Diaz</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Rangel-Zu&#241;iga</surname><given-names>O.</given-names></name><name name-style="western"><surname>Delgado-Lista</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yubero-Serrano</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Lopez-Moreno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tinahones</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Ordovas</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Garaulet</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Chronic Consumption of a Low-Fat Diet Improves Cardiometabolic Risk Factors According to the CLOCK Gene in Patients with Coronary Heart Disease</article-title><source>Mol. Nutr. Food Res.</source><year>2015</year><volume>59</volume><fpage>2556</fpage><lpage>2564</lpage><pub-id pub-id-type="doi">10.1002/mnfr.201500375</pub-id><pub-id pub-id-type="pmid">26346429</pub-id></element-citation></ref><ref id="B25-nutrients-17-02804"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulven</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Nyg&#229;rd</surname><given-names>O.</given-names></name><name name-style="western"><surname>Svardal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leder</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ottestad</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lysne</surname><given-names>V.</given-names></name><name name-style="western"><surname>Laupsa-Borge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ueland</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Midttun</surname><given-names>&#216;.</given-names></name><etal/></person-group><article-title>Using Metabolic Profiling and Gene Expression Analyses to Explore Molecular Effects of Replacing Saturated Fat with Polyunsaturated Fat&#8212;A Randomized Controlled Dietary Intervention Study</article-title><source>Am. J. Clin. Nutr.</source><year>2019</year><volume>109</volume><fpage>1239</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1093/ajcn/nqy356</pub-id><pub-id pub-id-type="pmid">31051508</pub-id><pub-id pub-id-type="pmcid">PMC6499508</pub-id></element-citation></ref><ref id="B26-nutrients-17-02804"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudkowska</surname><given-names>I.</given-names></name><name name-style="western"><surname>P&#233;russe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bellis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Blangero</surname><given-names>J.</given-names></name><name name-style="western"><surname>Despr&#233;s</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Bouchard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vohl</surname><given-names>M.-C.</given-names></name></person-group><article-title>Interaction between Common Genetic Variants and Total Fat Intake on Low-Density Lipoprotein Peak Particle Diameter: A Genome-Wide Association Study</article-title><source>Lifestyle Genom.</source><year>2015</year><volume>8</volume><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1159/000431151</pub-id><pub-id pub-id-type="pmid">26112879</pub-id></element-citation></ref><ref id="B27-nutrients-17-02804"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tremblay</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Cormier</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rudkowska</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lemieux</surname><given-names>S.</given-names></name><name name-style="western"><surname>Couture</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vohl</surname><given-names>M.-C.</given-names></name></person-group><article-title>Association between Polymorphisms in Phospholipase A 2 Genes and the Plasma Triglyceride Response to an N-3 PUFA Supplementation: A Clinical Trial</article-title><source>Lipids Health Dis.</source><year>2015</year><volume>14</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s12944-015-0009-2</pub-id><pub-id pub-id-type="pmid">25889305</pub-id><pub-id pub-id-type="pmcid">PMC4342012</pub-id></element-citation></ref><ref id="B28-nutrients-17-02804"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouellette</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rudkowska</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lemieux</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lamarche</surname><given-names>B.</given-names></name><name name-style="western"><surname>Couture</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vohl</surname><given-names>M.-C.</given-names></name></person-group><article-title>Gene-Diet Interactions with Polymorphisms of the MGLL Gene on Plasma Low-Density Lipoprotein Cholesterol and Size Following an Omega-3 Polyunsaturated Fatty Acid Supplementation: A Clinical Trial</article-title><source>Lipids Health Dis.</source><year>2014</year><volume>13</volume><fpage>86</fpage><pub-id pub-id-type="doi">10.1186/1476-511X-13-86</pub-id><pub-id pub-id-type="pmid">24884512</pub-id><pub-id pub-id-type="pmcid">PMC4040477</pub-id></element-citation></ref><ref id="B29-nutrients-17-02804"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vall&#233;e Marcotte</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cormier</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gu&#233;nard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rudkowska</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lemieux</surname><given-names>S.</given-names></name><name name-style="western"><surname>Couture</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vohl</surname><given-names>M.-C.</given-names></name></person-group><article-title>Novel Genetic Loci Associated with the Plasma Triglyceride Response to an Omega-3 Fatty Acid Supplementation</article-title><source>Lifestyle Genom.</source><year>2016</year><volume>9</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1159/000446024</pub-id><pub-id pub-id-type="pmid">27160456</pub-id></element-citation></ref><ref id="B30-nutrients-17-02804"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehramiz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ghasemi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Esmaily</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tayefi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hassanian</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Sadeghzade</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sadabadi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Moohebati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Azarpazhooh</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Parizadeh</surname><given-names>S.M.R.</given-names></name><etal/></person-group><article-title>Interaction between a Variant of CDKN2A/B-Gene with Lifestyle Factors in Determining Dyslipidemia and Estimated Cardiovascular Risk: A Step toward Personalized Nutrition</article-title><source>Clin. Nutr.</source><year>2018</year><volume>37</volume><fpage>254</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2016.12.018</pub-id><pub-id pub-id-type="pmid">28065479</pub-id></element-citation></ref><ref id="B31-nutrients-17-02804"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>French</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>J.M.</given-names></name></person-group><article-title>Optimising the Value of the Critical Appraisal Skills Programme (CASP) Tool for Quality Appraisal in Qualitative Evidence Synthesis</article-title><source>Res. Methods Med. Health Sci.</source><year>2020</year><volume>1</volume><fpage>31</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1177/2632084320947559</pub-id></element-citation></ref><ref id="B32-nutrients-17-02804"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nair</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Borkar</surname><given-names>N.K.</given-names></name></person-group><article-title>Various Biases in Systematic Review and Meta-Analysis and Their Assessment</article-title><source>Indian J. Anaesth.</source><year>2025</year><volume>69</volume><fpage>138</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.4103/ija.ija_1212_24</pub-id><pub-id pub-id-type="pmid">40046717</pub-id><pub-id pub-id-type="pmcid">PMC11878363</pub-id></element-citation></ref><ref id="B33-nutrients-17-02804"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boffetta</surname><given-names>P.</given-names></name><name name-style="western"><surname>Winn</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Ioannidis</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Little</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Cogliano</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Seminara</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vineis</surname><given-names>P.</given-names></name></person-group><article-title>Recommendations and Proposed Guidelines for Assessing the Cumulative Evidence on Joint Effects of Genes and Environments on Cancer Occurrence in Humans</article-title><source>Int. J. Epidemiol.</source><year>2012</year><volume>41</volume><fpage>686</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1093/ije/dys010</pub-id><pub-id pub-id-type="pmid">22596931</pub-id><pub-id pub-id-type="pmcid">PMC3481885</pub-id></element-citation></ref><ref id="B34-nutrients-17-02804"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sweeney</surname><given-names>T.</given-names></name><name name-style="western"><surname>Quispe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Das</surname><given-names>T.</given-names></name><name name-style="western"><surname>Juraschek</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Michos</surname><given-names>E.D.</given-names></name></person-group><article-title>The Use of Blood Biomarkers in Precision Medicine for the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Review</article-title><source>Expert. Rev. Precis. Med. Drug Dev.</source><year>2021</year><volume>6</volume><fpage>247</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1080/23808993.2021.1930531</pub-id><pub-id pub-id-type="pmid">34423130</pub-id><pub-id pub-id-type="pmcid">PMC8372373</pub-id></element-citation></ref><ref id="B35-nutrients-17-02804"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riley</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Sapp</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Kris-Etherton</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>K.S.</given-names></name></person-group><article-title>Effects of saturated fatty acid consumption on lipoprotein (a): A systematic review and meta-analysis of randomized controlled trials</article-title><source>Am. J. Clin. Nutr.</source><year>2024</year><volume>120</volume><fpage>619</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1016/j.ajcnut.2024.06.019</pub-id><pub-id pub-id-type="pmid">38964657</pub-id></element-citation></ref><ref id="B36-nutrients-17-02804"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nayor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Vasan</surname><given-names>R.S.</given-names></name></person-group><article-title>The Molecular Basis of Predicting Atherosclerotic Cardiovascular Disease Risk</article-title><source>Circ. Res.</source><year>2021</year><volume>128</volume><fpage>287</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.315890</pub-id><pub-id pub-id-type="pmid">33476202</pub-id><pub-id pub-id-type="pmcid">PMC7839236</pub-id></element-citation></ref><ref id="B37-nutrients-17-02804"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gareev</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kudriashov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sufianov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Begliarzade</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ilyasova</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Beylerli</surname><given-names>O.</given-names></name></person-group><article-title>The Role of Long Non-Coding RNA ANRIL in the Development of Atherosclerosis</article-title><source>Non-Coding RNA Res.</source><year>2022</year><volume>7</volume><fpage>212</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.ncrna.2022.09.002</pub-id><pub-id pub-id-type="pmid">36157350</pub-id><pub-id pub-id-type="pmcid">PMC9467859</pub-id></element-citation></ref><ref id="B38-nutrients-17-02804"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fit&#243;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Melander</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Toledo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Carp&#233;n&#233;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corella</surname><given-names>D.</given-names></name></person-group><article-title>Advances in Integrating Traditional and Omic Biomarkers When Analyzing the Effects of the Mediterranean Diet Intervention in Cardiovascular Prevention</article-title><source>Int. J. Mol. Sci.</source><year>2016</year><volume>17</volume><elocation-id>1469</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17091469</pub-id><pub-id pub-id-type="pmid">27598147</pub-id><pub-id pub-id-type="pmcid">PMC5037747</pub-id></element-citation></ref><ref id="B39-nutrients-17-02804"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solly</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Dimasi</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Bursill</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Psaltis</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.T.M.</given-names></name></person-group><article-title>MicroRNAs as Therapeutic Targets and Clinical Biomarkers in Atherosclerosis</article-title><source>J. Clin. Med.</source><year>2019</year><volume>8</volume><elocation-id>2199</elocation-id><pub-id pub-id-type="doi">10.3390/jcm8122199</pub-id><pub-id pub-id-type="pmid">31847094</pub-id><pub-id pub-id-type="pmcid">PMC6947565</pub-id></element-citation></ref><ref id="B40-nutrients-17-02804"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kura</surname><given-names>B.</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Slezak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>G.N.</given-names></name></person-group><article-title>The Influence of Diet on MicroRNAs That Impact Cardiovascular Disease</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>1509</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24081509</pub-id><pub-id pub-id-type="pmid">30999630</pub-id><pub-id pub-id-type="pmcid">PMC6514571</pub-id></element-citation></ref><ref id="B41-nutrients-17-02804"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jurgens</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Erdmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bezzina</surname><given-names>C.R.</given-names></name></person-group><article-title>Genome-Wide Association Studies of Cardiovascular Disease</article-title><source>Physiol. Rev.</source><year>2023</year><volume>103</volume><fpage>2039</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.1152/physrev.00024.2022</pub-id><pub-id pub-id-type="pmid">36634218</pub-id></element-citation></ref><ref id="B42-nutrients-17-02804"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedman</surname><given-names>&#197;.K.</given-names></name><name name-style="western"><surname>Mendelson</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Marioni</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Gustafsson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joehanes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Irvin</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sandling</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Epigenetic patterns in blood associated with lipid traits predict incident coronary heart disease events and are enriched for results from genome-wide association studies</article-title><source>Circ. Cardiovasc. Genet.</source><year>2017</year><volume>10</volume><fpage>e001487</fpage><pub-id pub-id-type="doi">10.1161/CIRCGENETICS.116.001487</pub-id><pub-id pub-id-type="pmid">28213390</pub-id><pub-id pub-id-type="pmcid">PMC5331877</pub-id></element-citation></ref><ref id="B43-nutrients-17-02804"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reyes-Soffer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ginsberg</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Berglund</surname><given-names>L.</given-names></name><name name-style="western"><surname>Duell</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Heffron</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Kamstrup</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Lloyd-Jones</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Marcovina</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Yeang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Koschinsky</surname><given-names>M.L.</given-names></name></person-group><article-title>Lipoprotein (a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement from the American Heart Association</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2022</year><volume>42</volume><fpage>e48</fpage><lpage>e60</lpage><pub-id pub-id-type="doi">10.1161/ATV.0000000000000147</pub-id><pub-id pub-id-type="pmid">34647487</pub-id><pub-id pub-id-type="pmcid">PMC9989949</pub-id></element-citation></ref><ref id="B44-nutrients-17-02804"><label>44.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Khovidhunkit</surname><given-names>W.</given-names></name></person-group><article-title>Lipoprotein (a)</article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.heart.org/en/health-topics/cholesterol/genetic-conditions/lipoprotein-a" ext-link-type="uri">https://www.heart.org/en/health-topics/cholesterol/genetic-conditions/lipoprotein-a</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-30">(accessed on 30 March 2025)</date-in-citation></element-citation></ref><ref id="B45-nutrients-17-02804"><label>45.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kostner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kostner</surname><given-names>G.M.</given-names></name></person-group><article-title>Lipoprotein (a): Metabolism, Pathophysiology, and Impact on Diabetes Mellitus</article-title><source>Lipoproteins in Diabetes Mellitus</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2023</year><fpage>247</fpage><lpage>274</lpage></element-citation></ref><ref id="B46-nutrients-17-02804"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kronenberg</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mora</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stroes</surname><given-names>E.S.G.</given-names></name><name name-style="western"><surname>Ference</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Arsenault</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Berglund</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dweck</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Koschinsky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mach</surname><given-names>F.</given-names></name></person-group><article-title>Lipoprotein (a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement</article-title><source>Eur. Heart J.</source><year>2022</year><volume>43</volume><fpage>3925</fpage><lpage>3946</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehac361</pub-id><pub-id pub-id-type="pmid">36036785</pub-id><pub-id pub-id-type="pmcid">PMC9639807</pub-id></element-citation></ref><ref id="B47-nutrients-17-02804"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enkhmaa</surname><given-names>B.</given-names></name><name name-style="western"><surname>Berglund</surname><given-names>L.</given-names></name></person-group><article-title>Lipoprotein (a) and Effects of Diet: Time for Reassessment</article-title><source>Nutrients</source><year>2025</year><volume>17</volume><elocation-id>1714</elocation-id><pub-id pub-id-type="doi">10.3390/nu17101714</pub-id><pub-id pub-id-type="pmid">40431454</pub-id><pub-id pub-id-type="pmcid">PMC12114232</pub-id></element-citation></ref><ref id="B48-nutrients-17-02804"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Courville</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Boring</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brychta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Darcey</surname><given-names>V.</given-names></name><name name-style="western"><surname>Forde</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Gharib</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Effect of a plant-based, low-fat diet versus an animal-based, ketogenic diet on ad libitum energy intake</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>344</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-01209-1</pub-id><pub-id pub-id-type="pmid">33479499</pub-id></element-citation></ref><ref id="B49-nutrients-17-02804"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fasolo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Di Gregoli</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maegdefessel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.L.</given-names></name></person-group><article-title>Non-Coding RNAs in Cardiovascular Cell Biology and Atherosclerosis</article-title><source>Cardiovasc. Res.</source><year>2019</year><volume>115</volume><fpage>1732</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvz203</pub-id><pub-id pub-id-type="pmid">31389987</pub-id><pub-id pub-id-type="pmcid">PMC7967706</pub-id></element-citation></ref><ref id="B50-nutrients-17-02804"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacDonald-Ramos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Ibarra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Monroy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miranda-R&#237;os</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cerb&#243;n</surname><given-names>M.</given-names></name></person-group><article-title>Effect of Dietary Fatty Acids on MicroRNA Expression Related to Metabolic Disorders and Inflammation in Human and Animal Trials</article-title><source>Nutrients</source><year>2021</year><volume>13</volume><elocation-id>1830</elocation-id><pub-id pub-id-type="doi">10.3390/nu13061830</pub-id><pub-id pub-id-type="pmid">34072137</pub-id><pub-id pub-id-type="pmcid">PMC8226960</pub-id></element-citation></ref><ref id="B51-nutrients-17-02804"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teixeira</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Pereira-da-Silva</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>R.C.</given-names></name></person-group><article-title>The Role of MiRNAs in the Diagnosis of Stable Atherosclerosis of Different Arterial Territories: A Critical Review</article-title><source>Front. Cardiovasc. Med.</source><year>2022</year><volume>9</volume><elocation-id>1040971</elocation-id><pub-id pub-id-type="doi">10.3389/fcvm.2022.1040971</pub-id><pub-id pub-id-type="pmid">36505351</pub-id><pub-id pub-id-type="pmcid">PMC9733725</pub-id></element-citation></ref><ref id="B52-nutrients-17-02804"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>C.-M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.-W.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C.-M.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Chua</surname><given-names>S.-K.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>W.-P.</given-names></name><name name-style="western"><surname>Shyu</surname><given-names>K.-G.</given-names></name></person-group><article-title>Chrysin Boosts KLF2 Expression through Suppression of Endothelial Cell-Derived Exosomal MicroRNA-92a in the Model of Atheroprotection</article-title><source>Eur. J. Nutr.</source><year>2021</year><volume>60</volume><fpage>4345</fpage><lpage>4355</lpage><pub-id pub-id-type="doi">10.1007/s00394-021-02593-1</pub-id><pub-id pub-id-type="pmid">34041583</pub-id></element-citation></ref><ref id="B53-nutrients-17-02804"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reyes-P&#233;rez</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Becerra</surname><given-names>K.</given-names></name><name name-style="western"><surname>Barr&#243;n-Cabrera</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mu&#241;oz-Valle</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Armend&#225;riz-Borunda</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mart&#237;nez-L&#243;pez</surname><given-names>E.</given-names></name></person-group><article-title>FADS1 Genetic Variant and Omega-3 Supplementation Are Associated with Changes in Fatty Acid Composition in Red Blood Cells of Subjects with Obesity</article-title><source>Nutrients</source><year>2024</year><volume>16</volume><elocation-id>3522</elocation-id><pub-id pub-id-type="doi">10.3390/nu16203522</pub-id><pub-id pub-id-type="pmid">39458515</pub-id><pub-id pub-id-type="pmcid">PMC11509948</pub-id></element-citation></ref><ref id="B54-nutrients-17-02804"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shuai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>Pathological Bases and Clinical Application of Long Non-coding RNAs in Cardiovascular Diseases</article-title><source>Hypertension</source><year>2021</year><volume>78</volume><fpage>16</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.16752</pub-id><pub-id pub-id-type="pmid">34058852</pub-id></element-citation></ref><ref id="B55-nutrients-17-02804"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H.Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.M.</given-names></name></person-group><article-title>Impact of high fat diet on long non-coding RNAs and messenger RNAs expression in the aortas of ApoE(&#8722;/&#8722;) mice</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><elocation-id>34161</elocation-id><pub-id pub-id-type="doi">10.1038/srep34161</pub-id><pub-id pub-id-type="pmid">27698357</pub-id><pub-id pub-id-type="pmcid">PMC5048419</pub-id></element-citation></ref><ref id="B56-nutrients-17-02804"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>S.-L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><etal/></person-group><article-title>The Gut Microbiome in Atherosclerotic Cardiovascular Disease</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>845</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-00900-1</pub-id><pub-id pub-id-type="pmid">29018189</pub-id><pub-id pub-id-type="pmcid">PMC5635030</pub-id></element-citation></ref><ref id="B57-nutrients-17-02804"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Samarraie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pichette</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>G.</given-names></name></person-group><article-title>Role of the Gut Microbiome in the Development of Atherosclerotic Cardiovascular Disease</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>5420</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24065420</pub-id><pub-id pub-id-type="pmid">36982492</pub-id><pub-id pub-id-type="pmcid">PMC10051145</pub-id></element-citation></ref><ref id="B58-nutrients-17-02804"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name></person-group><article-title>Gut Microbiome and Metabolites, the Future Direction of Diagnosis and Treatment of Atherosclerosis?</article-title><source>Pharmacol. Res.</source><year>2023</year><volume>187</volume><fpage>106586</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2022.106586</pub-id><pub-id pub-id-type="pmid">36460280</pub-id></element-citation></ref><ref id="B59-nutrients-17-02804"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>D.S.</given-names></name></person-group><article-title>Metabolomics for Investigating Physiological and Pathophysiological Processes</article-title><source>Physiol. Rev.</source><year>2019</year><volume>99</volume><fpage>1819</fpage><lpage>1875</lpage><pub-id pub-id-type="doi">10.1152/physrev.00035.2018</pub-id><pub-id pub-id-type="pmid">31434538</pub-id></element-citation></ref><ref id="B60-nutrients-17-02804"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Djekic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nicoll</surname><given-names>R.</given-names></name><name name-style="western"><surname>Novo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Henein</surname><given-names>M.</given-names></name></person-group><article-title>Metabolomics in Atherosclerosis</article-title><source>IJC Metab. Endocr.</source><year>2015</year><volume>8</volume><fpage>26</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.ijcme.2014.11.004</pub-id></element-citation></ref><ref id="B61-nutrients-17-02804"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.-W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Ann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cheon</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>E.-Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Joo</surname><given-names>H.-C.</given-names></name><etal/></person-group><article-title>Metabolic Phenotyping of Human Atherosclerotic Plaques: Metabolic Alterations and Their Biological Relevance in Plaque-Containing Aorta</article-title><source>Atherosclerosis</source><year>2018</year><volume>269</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2017.11.034</pub-id><pub-id pub-id-type="pmid">29253644</pub-id></element-citation></ref><ref id="B62-nutrients-17-02804"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vorkas</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Shalhoub</surname><given-names>J.</given-names></name><name name-style="western"><surname>Isaac</surname><given-names>G.</given-names></name><name name-style="western"><surname>Want</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>E.</given-names></name></person-group><article-title>Metabolic phenotyping of atherosclerotic plaques reveals latent associations between free cholesterol and ceramide metabo-lism in atherogenesis</article-title><source>J. Proteome Res.</source><year>2015</year><volume>14</volume><fpage>1389</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1021/pr5009898</pub-id><pub-id pub-id-type="pmid">25565173</pub-id></element-citation></ref><ref id="B63-nutrients-17-02804"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edsfeldt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dun&#233;r</surname><given-names>P.</given-names></name><name name-style="western"><surname>St&#229;hlman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mollet</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Asciutto</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grufman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nitulescu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Persson</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Melander</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Sphingolipids Contribute to Human Atherosclerotic Plaque Inflammation</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2016</year><volume>36</volume><fpage>1132</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.116.305675</pub-id><pub-id pub-id-type="pmid">27055903</pub-id></element-citation></ref><ref id="B64-nutrients-17-02804"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Balram</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name></person-group><article-title>Convergence: Lactosylceramide-Centric Signaling Pathways Induce Inflammation, Oxidative Stress, and Other Phenotypic Outcomes</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>1816</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22041816</pub-id><pub-id pub-id-type="pmid">33673027</pub-id><pub-id pub-id-type="pmcid">PMC7917694</pub-id></element-citation></ref><ref id="B65-nutrients-17-02804"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gengatharan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Handzlik</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Chih</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Ruchhoeft</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Secrest</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ashley</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Green</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gordts</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Metallo</surname><given-names>C.M.</given-names></name></person-group><article-title>Altered sphingolipid biosynthetic flux and lipoprotein trafficking contribute to trans-fat-induced atherosclerosis</article-title><source>Cell Metab.</source><year>2025</year><volume>37</volume><fpage>274</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2024.10.016</pub-id><pub-id pub-id-type="pmid">39547233</pub-id><pub-id pub-id-type="pmcid">PMC12276992</pub-id></element-citation></ref><ref id="B66-nutrients-17-02804"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lechner</surname><given-names>K.</given-names></name><name name-style="western"><surname>von Schacky</surname><given-names>C.</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Worm</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nixdorff</surname><given-names>U.</given-names></name><name name-style="western"><surname>Lechner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kr&#228;nkel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Halle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Krauss</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Scherr</surname><given-names>J.</given-names></name></person-group><article-title>Lifestyle Factors and High-Risk Atherosclerosis: Pathways and Mechanisms beyond Traditional Risk Factors</article-title><source>Eur. J. Prev. Cardiol.</source><year>2019</year><volume>27</volume><fpage>394</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1177/2047487319869400</pub-id><pub-id pub-id-type="pmid">31408370</pub-id><pub-id pub-id-type="pmcid">PMC7065445</pub-id></element-citation></ref><ref id="B67-nutrients-17-02804"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riccardi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Giosu&#232;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Calabrese</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vaccaro</surname><given-names>O.</given-names></name></person-group><article-title>Dietary Recommendations for Prevention of Atherosclerosis</article-title><source>Cardiovasc. Res.</source><year>2022</year><volume>118</volume><fpage>1188</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvab173</pub-id><pub-id pub-id-type="pmid">34229346</pub-id></element-citation></ref><ref id="B68-nutrients-17-02804"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fanaroff</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Califf</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Windecker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>R.D.</given-names></name></person-group><article-title>Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018</article-title><source>JAMA</source><year>2019</year><volume>321</volume><fpage>1069</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1001/jama.2019.1122</pub-id><pub-id pub-id-type="pmid">30874755</pub-id><pub-id pub-id-type="pmcid">PMC6439920</pub-id></element-citation></ref><ref id="B69-nutrients-17-02804"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samuel</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Edo</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Emakpor</surname><given-names>O.L.</given-names></name><name name-style="western"><surname>Oloni</surname><given-names>G.O.</given-names></name><name name-style="western"><surname>Ezekiel</surname><given-names>G.O.</given-names></name><name name-style="western"><surname>Essaghah</surname><given-names>A.E.A.</given-names></name><name name-style="western"><surname>Agoh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Agbo</surname><given-names>J.J.</given-names></name></person-group><article-title>Lifestyle Modifications for Preventing and Managing Cardiovascular Diseases</article-title><source>Sport. Sci. Health</source><year>2024</year><volume>20</volume><fpage>23</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1007/s11332-023-01118-z</pub-id></element-citation></ref><ref id="B70-nutrients-17-02804"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mullins</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Bresette</surname><given-names>W.</given-names></name><name name-style="western"><surname>Johnstone</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hallmark</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chilton</surname><given-names>F.H.</given-names></name></person-group><article-title>Genomics in Personalized Nutrition: Can You &#8220;Eat for Your Genes&#8221;?</article-title><source>Nutrients</source><year>2020</year><volume>12</volume><elocation-id>3118</elocation-id><pub-id pub-id-type="doi">10.3390/nu12103118</pub-id><pub-id pub-id-type="pmid">33065985</pub-id><pub-id pub-id-type="pmcid">PMC7599709</pub-id></element-citation></ref><ref id="B71-nutrients-17-02804"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatelan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bochud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frohlich</surname><given-names>K.L.</given-names></name></person-group><article-title>Precision Nutrition: Hype or Hope for Public Health Interventions to Reduce Obesity?</article-title><source>Int. J. Epidemiol.</source><year>2019</year><volume>48</volume><fpage>332</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1093/ije/dyy274</pub-id><pub-id pub-id-type="pmid">30544190</pub-id><pub-id pub-id-type="pmcid">PMC6469305</pub-id></element-citation></ref><ref id="B72-nutrients-17-02804"><label>72.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Ordov&#225;s</surname><given-names>J.</given-names></name></person-group><article-title>A Multifaceted Approach to Precision Nutrition: The Genome, Epigenome, and Microbiome in the Prevention and Therapy of Cardiovascular Diseases</article-title><source>Precision Nutrition</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2024</year><fpage>181</fpage><lpage>200</lpage></element-citation></ref><ref id="B73-nutrients-17-02804"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#246;ring</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Noels</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>C.</given-names></name></person-group><article-title>The Use of High-Throughput Technologies to Investigate Vascular Inflammation and Atherosclerosis</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2012</year><volume>32</volume><fpage>182</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.111.232686</pub-id><pub-id pub-id-type="pmid">22258901</pub-id></element-citation></ref><ref id="B74-nutrients-17-02804"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vesnina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Prosekov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Atuchin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Minina</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ponasenko</surname><given-names>A.</given-names></name></person-group><article-title>Tackling Atherosclerosis via Selected Nutrition</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>8233</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23158233</pub-id><pub-id pub-id-type="pmid">35897799</pub-id><pub-id pub-id-type="pmcid">PMC9368664</pub-id></element-citation></ref><ref id="B75-nutrients-17-02804"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos-Lopez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Milagro</surname><given-names>F.I.</given-names></name><name name-style="western"><surname>Riezu-Boj</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>J.A.</given-names></name></person-group><article-title>Epigenetic Signatures Underlying Inflammation: An Interplay of Nutrition, Physical Activity, Metabolic Diseases, and Environmental Factors for Personalized Nutrition</article-title><source>Inflamm. Res.</source><year>2021</year><volume>70</volume><fpage>29</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1007/s00011-020-01425-y</pub-id><pub-id pub-id-type="pmid">33231704</pub-id><pub-id pub-id-type="pmcid">PMC7684853</pub-id></element-citation></ref><ref id="B76-nutrients-17-02804"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandaviya</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Stolk</surname><given-names>L.</given-names></name><name name-style="western"><surname>Heil</surname><given-names>S.G.</given-names></name></person-group><article-title>Homocysteine and DNA Methylation: A Review of Animal and Human Literature</article-title><source>Mol. Genet. Metab.</source><year>2014</year><volume>113</volume><fpage>243</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2014.10.006</pub-id><pub-id pub-id-type="pmid">25456744</pub-id></element-citation></ref><ref id="B77-nutrients-17-02804"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aavik</surname><given-names>E.</given-names></name><name name-style="western"><surname>Babu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yl&#228;-Herttuala</surname><given-names>S.</given-names></name></person-group><article-title>DNA Methylation Processes in Atherosclerotic Plaque</article-title><source>Atherosclerosis</source><year>2019</year><volume>281</volume><fpage>168</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2018.12.006</pub-id><pub-id pub-id-type="pmid">30591183</pub-id></element-citation></ref><ref id="B78-nutrients-17-02804"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boughanem</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bandera-Merch&#225;n</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Alonso</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moreno-Morales</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tinahones</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Lozano</surname><given-names>J.</given-names></name><name name-style="western"><surname>Morcillo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Macias-Gonzalez</surname><given-names>M.</given-names></name></person-group><article-title>Association between the APOA2 Rs3813627 Single Nucleotide Polymorphism and HDL and APOA1 Levels through BMI</article-title><source>Biomedicines</source><year>2020</year><volume>8</volume><elocation-id>44</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines8030044</pub-id><pub-id pub-id-type="pmid">32120838</pub-id><pub-id pub-id-type="pmcid">PMC7148512</pub-id></element-citation></ref><ref id="B79-nutrients-17-02804"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desjardins</surname><given-names>L.-C.</given-names></name><name name-style="western"><surname>Vohl</surname><given-names>M.-C.</given-names></name></person-group><article-title>Precision Nutrition for Cardiovascular Disease Prevention</article-title><source>Lifestyle Genom.</source><year>2023</year><volume>16</volume><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1159/000529054</pub-id></element-citation></ref><ref id="B80-nutrients-17-02804"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finicelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Salle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Galderisi</surname><given-names>U.</given-names></name><name name-style="western"><surname>Peluso</surname><given-names>G.</given-names></name></person-group><article-title>The Mediterranean Diet: An Update of the Clinical Trials</article-title><source>Nutrients</source><year>2022</year><volume>14</volume><elocation-id>2956</elocation-id><pub-id pub-id-type="doi">10.3390/nu14142956</pub-id><pub-id pub-id-type="pmid">35889911</pub-id><pub-id pub-id-type="pmcid">PMC9317652</pub-id></element-citation></ref><ref id="B81-nutrients-17-02804"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corella</surname><given-names>D.</given-names></name><name name-style="western"><surname>Coltell</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mattingley</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sorli</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Ordovas</surname><given-names>J.M.</given-names></name></person-group><article-title>Utilizing Nutritional Genomics to Tailor Diets for the Prevention of Cardiovascular Disease: A Guide for Upcoming Studies and Implementations</article-title><source>Expert. Rev. Mol. Diagn.</source><year>2017</year><volume>17</volume><fpage>495</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1080/14737159.2017.1311208</pub-id><pub-id pub-id-type="pmid">28337931</pub-id></element-citation></ref><ref id="B82-nutrients-17-02804"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenson</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Hirsh</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Kathiresan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gaudet</surname><given-names>D.</given-names></name></person-group><article-title>Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease</article-title><source>J. Am. Coll. Cardiol.</source><year>2014</year><volume>64</volume><fpage>2525</fpage><lpage>2540</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2014.09.042</pub-id><pub-id pub-id-type="pmid">25500239</pub-id></element-citation></ref><ref id="B83-nutrients-17-02804"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acharjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tomar</surname><given-names>R.S.</given-names></name></person-group><article-title>Mechanisms of DNA Methylation and Histone Modifications</article-title><source>Prog. Mol. Biol. Transl. Sci.</source><year>2023</year><volume>197</volume><fpage>51</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">37019597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.pmbts.2023.01.001</pub-id></element-citation></ref><ref id="B84-nutrients-17-02804"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussain</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Abdullah</surname></name><name name-style="western"><surname>Khan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alsharif</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Alzahrani</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Saso</surname><given-names>L.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>H.</given-names></name></person-group><article-title>Regulatory Effects of Curcumin on Platelets: An Update and Future Directions</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><elocation-id>3180</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10123180</pub-id><pub-id pub-id-type="pmid">36551934</pub-id><pub-id pub-id-type="pmcid">PMC9775400</pub-id></element-citation></ref><ref id="B85-nutrients-17-02804"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marcum</surname><given-names>J.A.</given-names></name></person-group><article-title>Nutrigenetics/Nutrigenomics, Personalized Nutrition, and Precision Healthcare</article-title><source>Curr. Nutr. Rep.</source><year>2020</year><volume>9</volume><fpage>338</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1007/s13668-020-00327-z</pub-id><pub-id pub-id-type="pmid">32578026</pub-id></element-citation></ref><ref id="B86-nutrients-17-02804"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Louca</surname><given-names>P.</given-names></name><name name-style="western"><surname>Menni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Padmanabhan</surname><given-names>S.</given-names></name></person-group><article-title>Genomic Determinants of Hypertension with a Focus on Metabolomics and the Gut Microbiome</article-title><source>Am. J. Hypertens.</source><year>2020</year><volume>33</volume><fpage>473</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1093/ajh/hpaa022</pub-id><pub-id pub-id-type="pmid">32060494</pub-id><pub-id pub-id-type="pmcid">PMC7241940</pub-id></element-citation></ref><ref id="B87-nutrients-17-02804"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramzan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vickers</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Mithen</surname><given-names>R.F.</given-names></name></person-group><article-title>Epigenetics, MicroRNA and Metabolic Syndrome: A Comprehensive Review</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>5047</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22095047</pub-id><pub-id pub-id-type="pmid">34068765</pub-id><pub-id pub-id-type="pmcid">PMC8126218</pub-id></element-citation></ref><ref id="B88-nutrients-17-02804"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lichtenstein</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Vadiveloo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Kris-Etherton</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Rebholz</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Sacks</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Thorndike</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Van Horn</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wylie-Rosett</surname><given-names>J.</given-names></name></person-group><article-title>2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement from the American Heart Association</article-title><source>Circulation</source><year>2021</year><volume>144</volume><fpage>e472</fpage><lpage>e487</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000001031</pub-id><pub-id pub-id-type="pmid">34724806</pub-id></element-citation></ref><ref id="B89-nutrients-17-02804"><label>89.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>W.B.</given-names></name></person-group><article-title>Understanding Human Disease in the Post-Genomic Era</article-title><source>Essential Concepts in Molecular Pathology</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2020</year><fpage>101</fpage><lpage>111</lpage></element-citation></ref><ref id="B90-nutrients-17-02804"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ceriani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Montalvan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Quintero</surname><given-names>B.</given-names></name><name name-style="western"><surname>Su&#225;rez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bautista-Valarezo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Frias-Toral</surname><given-names>E.</given-names></name></person-group><article-title>Ethics of the Clinical Practice of Nutrigenetics and Nutrigenomics</article-title><source>Clin. Nutr. Open Sci.</source><year>2023</year><volume>49</volume><fpage>58</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.nutos.2023.04.006</pub-id></element-citation></ref><ref id="B91-nutrients-17-02804"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brennan</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Roos</surname><given-names>B.</given-names></name></person-group><article-title>Nutrigenomics: Lessons Learned and Future Perspectives</article-title><source>Am. J. Clin. Nutr.</source><year>2021</year><volume>113</volume><fpage>503</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1093/ajcn/nqaa366</pub-id><pub-id pub-id-type="pmid">33515029</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="nutrients-17-02804-f001" orientation="portrait"><label>Figure 1</label><caption><p>PRISMA flow diagram depicting the identification, screening, and selection of studies for this systematic review.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-17-02804-g001.jpg"/></fig><fig position="float" id="nutrients-17-02804-f002" orientation="portrait"><label>Figure 2</label><caption><p>Forest plot illustrating the standardized mean difference (SMD) in triglyceride (TG) levels before and after omega-3 PUFA supplementation [<xref rid="B19-nutrients-17-02804" ref-type="bibr">19</xref>,<xref rid="B28-nutrients-17-02804" ref-type="bibr">28</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-17-02804-g002.jpg"/></fig><fig position="float" id="nutrients-17-02804-f003" orientation="portrait"><label>Figure 3</label><caption><p>Forest plot comparing the effect of Mediterranean diet (MedDiet) versus low-fat diet on lipid outcomes across different genotypes [<xref rid="B18-nutrients-17-02804" ref-type="bibr">18</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-17-02804-g003.jpg"/></fig><fig position="float" id="nutrients-17-02804-f004" orientation="portrait"><label>Figure 4</label><caption><p>Mechanism depicting the role of ANRIL in atherosclerosis. Distinct transcripts of the ANRIL gene protect and promote atherosclerosis development and progression.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-17-02804-g004.jpg"/></fig><fig position="float" id="nutrients-17-02804-f005" orientation="portrait"><label>Figure 5</label><caption><p>LacCer activates NADPH oxidase, creating ROS and with heightened oxidative stress, generating a significant number of reactive oxygen species that trigger various kinds of signalling molecules, followed by cascade receptivity; as a result, many different phenotypes begin to emerge (including atherosclerosis).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-17-02804-g005.jpg"/></fig><table-wrap position="float" id="nutrients-17-02804-t001" orientation="portrait"><object-id pub-id-type="pii">nutrients-17-02804-t001_Table 1</object-id><label>Table 1</label><caption><p>Inclusion and exclusion criteria used for drafting the systematic review.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Criteria</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Inclusion</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Exclusion</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Population</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults (&#8805;18 years) with diagnosed atherosclerosis or at high risk of CVD.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Children, adolescents (&lt;18 years), or unrelated populations (e.g., cancer patients, non-CVD conditions).</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intervention</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Personalized nutrition interventions considering individual omics profiling (genetics, microbiome, metabolomics, epigenetics).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Generalized or non-personalized dietary advice.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Comparison</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Standard care diets or control groups.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Studies without a comparison group.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Outcomes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measured effects on atherosclerosis-related clinical outcomes, biomarkers, or metabolic profiles.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Studies that do not measure or report relevant clinical, metabolic, or biomarker outcomes.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study Design</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary studies only: randomized controlled trials (RCTs); cohort studies; case&#8211;control, cross-sectional studies with analytical focus.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Narrative reviews, systematic reviews, meta-analyses, opinion pieces, and conference abstracts without full papers.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Language</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Studies published in English.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-English publications without available translations.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Publication Date</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Studies published within the last 10 years (to capture contemporary personalized nutrition advancements).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Studies older than 10 years.</td></tr></tbody></table></table-wrap><table-wrap position="float" id="nutrients-17-02804-t002" orientation="portrait"><object-id pub-id-type="pii">nutrients-17-02804-t002_Table 2</object-id><label>Table 2</label><caption><p>Summary and characteristics of the included studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Study</bold>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Country</bold>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Sample/Population</bold>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Study Design</bold>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample Size</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Intervention</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Duration</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcome Measured</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene/Genetic Variant Tested</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Findings</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B17-nutrients-17-02804" ref-type="bibr">17</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Healthy subjects with and without subclinical atherosclerosis (SA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional exploratory study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 Chinese subjects (46 female, 54 male)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed-meal test (low-fat (energy% &lt; 30%) frozen meal)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">164 blood biomarkers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Omics model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SA could not be accurately predicted using models, and it depends only on fasting biomarkers or baseline clinical characteristics. Conversely, an omics model based on the timing and quantity of postprandial biomarkers showed excellent performance [ROC AUC: 91%; 95% CI: 77&#8211;100].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B18-nutrients-17-02804" ref-type="bibr">18</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHD Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CORDIOPREV study (RCT)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">506 (male = 433, female = 73)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mediterranean diet and Low-fat diet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Postprandial TG and TRLs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">APOE rs439401, rs440446, rs7412</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Using a gene&#8211;diet approach, the study analysed the interaction between the <italic toggle="yes">APOE rs439401</italic> SNP and the MedDiet. <break/>Compared to CC patients, those in the MedDiet group who were carriers of the T-allele displayed a more significant decrease in postprandial triglycerides (TG: <italic toggle="yes">p</italic> = 0.03), as well as large triacylglycerol-rich lipoproteins (TRLs) TG (large TRLs TG; <italic toggle="yes">p</italic> = 0.01. Both the TG area under the curve (AUC-TG; P-interaction = 0.03) and the AUC-large TRLs TG (P-interaction = 0.02) showed consistent patterns that were significantly lower in T-allele carriers compared with levels in CC subjects.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B19-nutrients-17-02804" ref-type="bibr">19</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quebec, Canada</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Caucasian subjects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interventional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">208</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Omega-3 supplementation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 years, <break/> 3 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma lipids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 SNPs in <italic toggle="yes">IQCJ</italic>, 34 in <italic toggle="yes">NXPH1</italic>, 8 in <italic toggle="yes">PHF17</italic>, and 9 in <italic toggle="yes">MYB</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The genotype risk score (GRS) accounted for 49.73 percent of the variation in TG response (<italic toggle="yes">p</italic> &lt; 0.0001) in a general linear model that adjusted for age, sex, and body mass index.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B20-nutrients-17-02804" ref-type="bibr">20</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New York and Los Angeles, USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">White, Caucasian<break/>Black, African-American<break/>Hispanic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">987 (male: 469, <break/> female: 518)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma homocysteine, micronutrients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Long interspersed nucleotide 1 (<italic toggle="yes">LINE-1</italic>) and <italic toggle="yes">Alu</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The LINE-1 methylation was 0.05 (0.01, 0.13), %5 mC higher for every 3 mmol/L increase in homocysteine. Furthermore, a positive correlation (<italic toggle="yes">p</italic> trend = 0.03) was found between BMI and <italic toggle="yes">LINE-1</italic> methylation. The <italic toggle="yes">LINE-1</italic> was 0.35 (0.03, 0.67), %5 mC higher in participants with a 40 kg/m<sup>2</sup> BMI than in those with a normal BMI. A variation of 0.10 (0.02, 0.19), %5 mC in <italic toggle="yes">Alu</italic> methylation was also noted for every 10 cm of height.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-nutrients-17-02804" ref-type="bibr">21</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quebec, Canada</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Middle-aged adults at higher risk of developing chronic diseases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CARTaGENE biobank (12,065)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>-</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid profile and intakes (%kcal/day) of total, saturated (SFA), monounsaturated (MUFA), and polyunsaturated (PUFA) fatty acids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">CD36</italic> gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Habitual fat consumption is linked to CD36 variations, which might explain later relationships with biomarkers associated with chronic diseases. Higher consumption of SFA was linked to <italic toggle="yes">rs1054516</italic> and <italic toggle="yes">rs3173798</italic> (both <italic toggle="yes">p</italic> &#8201;&lt; &#8201;0.05), and <italic toggle="yes">rs1054516</italic> was also linked to higher levels of serum triglycerides (<italic toggle="yes">p</italic>&#8201; = &#8201;0.0065).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B22-nutrients-17-02804" ref-type="bibr">22</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients without a history of cardiovascular disease but at high cardiovascular risk</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mediterranean diet for primary prevention of cardiovascular diseases<break/>(Prevenci&#243;n con DietaMediterr&#225;nea) randomized trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">521</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mediterranean Diet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Telomere length</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">PPAR&#947;2</italic> locus, <italic toggle="yes">rs1801282</italic>, <italic toggle="yes">Ala</italic> allele</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After five years of follow-up, the <italic toggle="yes">pro12Ala</italic> polymorphism is linked to TL homeostasis in persons at high cardiovascular risk. Furthermore, among Ala carriers, a stronger defence against telomere shortening is provided by a higher level of adherence to the MeDiet pattern.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-nutrients-17-02804" ref-type="bibr">23</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Germany</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monocyte/macrophage cell line RAW264.7 and the endothelial cell line TIME</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro experiment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Docosahexaenoic acid (DHA; <italic toggle="yes">n</italic>-3-PUFA) or arachidonic acid (AA; <italic toggle="yes">n</italic>-6-PUFA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">miRNAs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">miRNAs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PUFAs affect miRNA expression in both cell types under investigation, regardless of the presence of an inflammatory stimulant. Moreover, it was shown that cellular PUFA enrichment had an impact on certain miRNAs previously connected to vascular inflammation.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B24-nutrients-17-02804" ref-type="bibr">24</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHD Patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CORDIOPREV study (RCT)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">897</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low-fat (LF) diet and Mediterranean diet (MedDiet)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hs-CRP, HDL/ApoA1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">CLOCK</italic> SNPs <italic toggle="yes">(rs1801260</italic>, <italic toggle="yes">rs3749474</italic>, <italic toggle="yes">rs4580704)</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The LF diet and the <italic toggle="yes">rs4580704</italic> SNP interact to improve the inflammation and dyslipidaemia associated with CHD. Compared to minor G allele carriers (G/G + C/G), major allele carriers C/C showed a higher drop in high-sensitivity C-reactive protein (<italic toggle="yes">p</italic> &lt; 0.001) and a substantial rise in HDL/apolipoprotein A1 ratio (<italic toggle="yes">p</italic> = 0.029).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-nutrients-17-02804" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oslo, Norway</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PUFAs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipoprotein subclasses, bile acids, proprotein convertase subtilisin/kexin type 9, acetate, and acetoacetate </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA levels of <italic toggle="yes">LXRA</italic> and <italic toggle="yes">LDLR</italic>, <italic toggle="yes">UCP2</italic>, and <italic toggle="yes">PPARD</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subclasses of lipoproteins, myristoyl- and palmitoyl-carnitine, and kynurenine decreased when PUFAs were substituted for SFAs. On the other hand, the intervention raised the levels of acetoacetate, bile acids, proprotein convertase subtilisin/kexin type 9, and acetate. The intervention also changed a few amino acids. After substituting SFAs with PUFAs, peripheral blood mononuclear cells showed a drop in the mRNA levels of <italic toggle="yes">UCP2</italic> and <italic toggle="yes">PPARD</italic> and an increase in the mRNA levels of <italic toggle="yes">LXRA</italic> and <italic toggle="yes">LDLR</italic>, along with many genes implicated in inflammation and liver X receptor alpha target genes.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-nutrients-17-02804" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quebec, Canada</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults from Quebec Family Study (QFS)&#8212;observational</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quebec Family Study (QFS)&#8212;observational</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">541</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total fat intake; LDL-PPD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNPs from a genome-wide association study (GWAS)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">There is an interaction between dietary fat consumption and various SNPs in terms of variation in the LDL-PPD.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-nutrients-17-02804" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quebec, Canada</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults (18&#8211;50 years)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interventional study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">208</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 g/day of <italic toggle="yes">n</italic>-3 PUFA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TG levels</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 SNPs in <italic toggle="yes">PLA2G2A</italic>, 6 in <italic toggle="yes">PLA2G2C</italic>, 8 in <italic toggle="yes">PLA2G2D</italic>, 6 in <italic toggle="yes">PLA2G2F</italic>, 22 in <italic toggle="yes">PLA2G4A</italic>, 5 in <italic toggle="yes">PLA2G6</italic>, and 9 in <italic toggle="yes">PLA2G7</italic> were genotyped</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">These results suggest that SNPs in <italic toggle="yes">PLA2</italic> genes could influence plasma TG levels when supplemented with <italic toggle="yes">n</italic>-3 PUFA.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-nutrients-17-02804" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quebec, Canada</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults (18&#8211;50 years)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interventional study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">210</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 g/d of a fish oil supplement</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LDL-C, particle size</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 SNPs of the <italic toggle="yes">MGLL</italic> gene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">After supplementation with <italic toggle="yes">n</italic>-3 PUFA, plasma LDL-C levels and particle size may be modified by polymorphisms in the <italic toggle="yes">MGLL</italic> gene.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-nutrients-17-02804" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quebec, Canada</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults (18&#8211;50 years)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interventional study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">208</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 g/day of fish oil</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6-week</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma TG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SNPs: <italic toggle="yes">IQCJ, NXPH1, PHF17</italic> and <italic toggle="yes">MYB</italic> genes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Using fine-mapping at GWAS-associated loci, SNPs partially explaining the significant interindividual heterogeneity in plasma TG levels induced by an <italic toggle="yes">n</italic>-3 FA supplementation were identified.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-nutrients-17-02804" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Iran</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mashhad Stroke and Heart Atherosclerotic Disorders (MASHAD) cohort study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1165</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CVD risk, lipids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">CDKN2A/B-rs10811661</italic> locus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A strong correlation was observed between cardiovascular risk variables and dyslipidaemia, as well as the <italic toggle="yes">CDKN2A-rs10811661</italic> polymorphism.</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: AA = Arachidonic Acid; <italic toggle="yes">ApoA1</italic> = Apolipoprotein A1; APOE = Apolipoprotein E; CHD = Coronary Heart Disease; CI = Confidence Interval; <italic toggle="yes">CLOCK</italic> = Circadian Locomotor Output Cycles Kaput; CRP = C-Reactive Protein; CVD = Cardiovascular Disease; DHA = Docosahexaenoic Acid; GWAS = Genome-Wide Association Study; GRS = Genetic Risk Score; HDL-C = High-Density Lipoprotein Cholesterol; LDL-C = Low-Density Lipoprotein Cholesterol; LDL-PPD = Low-Density Lipoprotein Peak Particle Diameter; <italic toggle="yes">LINE-1</italic> = Long Interspersed Nuclear Elements-1; LF = Low-Fat; MedDiet (MeDiet) = Mediterranean Diet; <italic toggle="yes">MGLL</italic> = Monoglyceride Lipase; miRNA = MicroRNA; MUFA = Monounsaturated Fatty Acids; <italic toggle="yes">n</italic>-3 PUFA = Omega-3 Polyunsaturated Fatty Acids; <italic toggle="yes">n</italic>-6 PUFA = Omega-6 Polyunsaturated Fatty Acids; PUFA = Polyunsaturated Fatty Acids; <italic toggle="yes">PPAR&#947;2</italic> = Peroxisome Proliferator-Activated Receptor Gamma 2; QFS = Quebec Family Study; RCT = Randomized Controlled Trial; SA = Subclinical Atherosclerosis; SFA = Saturated Fatty Acids; SNP = Single Nucleotide Polymorphism; TG = Triglycerides; TRLs = Triacylglycerol-Rich Lipoproteins.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="nutrients-17-02804-t003" orientation="portrait"><object-id pub-id-type="pii">nutrients-17-02804-t003_Table 3</object-id><label>Table 3</label><caption><p>Evidence-based, personalized biomarkers associated with atherosclerosis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Biomarker Categories</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Biological Markers</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism/Aspects of Personalized Nutrition</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcome</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Genetic Markers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipoprotein (a)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The LPA gene, in particular, plays a major role in determining Lp(a) levels, but other treatments have also been proven to affect them.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lp(a) significantly increases the risk of ASCVD that remains after statin treatment in individuals.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-nutrients-17-02804" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutations in PCSK9 (proprotein convertase subtilisin/kexin type 9) Protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lowers the amounts of LDLR expressed in peripheral tissues or the liver, which indirectly obstructs the absorption of LDL by hepatocytes and other tissues.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interference with molecular pathways during the onset and development of atherosclerotic plaque</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-nutrients-17-02804" ref-type="bibr">35</xref>,<xref rid="B36-nutrients-17-02804" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antisense noncoding RNA in the INK4 locus (ANRIL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Regulate the division and death of cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change the arterial plaque size and the apoptotic debris removal process</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-nutrients-17-02804" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CDKN2A/2B Rs10811661 (C/T) polymorphism</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A TT genotype has been linked to a higher risk of CVD, insulin resistance, and hypercholesterolemia. These effects were more noticeable in the subgroup with low physical activity levels and high dietary energy intake.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Genetic variation increases the risk of cardiovascular disease and dyslipidemia.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-nutrients-17-02804" ref-type="bibr">30</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ANRIL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modify chromatin to control the growth of vascular smooth muscle cells (VSMCs) in plaques. Additionally, alter transcriptional levels to impact macrophage proliferation and death.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atherosclerotic plaque growth is tightly linked to the proliferation and death of related cells.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-nutrients-17-02804" ref-type="bibr">37</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Circulating miRNAs</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">A PUFA-enriched normocaloric diet is linked to modifications in the circulating profile of miRNA.<break/>A high-fat diet demonstrated how TGRL uses miRNA to sway the endothelium pro-inflammatory response.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreased miR-21, miR-30, miR-126 and miR-221-3p; and increased miR-21, miR-92a and miR-99a with the progression and degradation of atherosclerosis phenotypes</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B38-nutrients-17-02804" ref-type="bibr">38</xref>,<xref rid="B39-nutrients-17-02804" ref-type="bibr">39</xref>,<xref rid="B40-nutrients-17-02804" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">miR-24</italic><break/><italic toggle="yes">miR-122</italic><break/><italic toggle="yes">miR-185</italic><break/><italic toggle="yes">miR-223</italic><break/><italic toggle="yes">miR-486</italic><break/>Cholesterol homeostasis and reverse cholesterol transport</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">miR-155</italic><break/><italic toggle="yes">miR-378a</italic><break/>Plaque rupture in atherosclerosis</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>